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Introduction 
Type 2 Diabetes Mellitus (T2DM) is a modern metabolic disorder with increasing number of 
patients over the last decades, and at present even reaching pandemic levels (Wang et al., 
2011). Hyperglycemia, insulin resistance and impaired insulin production are the 
characteristics of T2DM (Olokoba et al., 2012; Lazar, 2007; Ferrannini, 1992). Insulin 
resistance is the inability to execute efficient glucose uptake by the insulin sensitive organs. 
T2DM results in disequilibrium of glucose in the body and consequently a disequilibrium in 
energy and lipid homeostasis. The development of T2DM can be affected by genomic, 
environmental and behavioral risk factors (Olokoba et al., 2012; Chen et al., 2011). 
The aim of the present thesis was to define novel targets for the possible development of 
drugs for T2DM, and to this end this first chapter presents an overview of insulin function and 
adipose tissue as the modes of action underlying the adverse effects in T2DM. The chapter 
also describes the possible drugs for treatment of T2DM, thiazolidinediones (TZDs) used so 
far, their mode of action and apparent issues that arose from their use pointing at the need for 
the development of other targets for drug development than TZDs. 
Insulin function 
Insulin influences synthesis of glycogen, fatty acids, proteins very likely all through transport 
of glucose. As a result insulin can influence cellular development including adipocytes 
differentiation. (Kahn and Flier, 2000; Jung and Choi, 2014). Insulin is produced by the β-
cells which are located in the islets of Langerhans in the pancreas. Whenever there is an 
excess of glucose in the blood, β-cells release insulin. Initially insulin binds to the insulin 
receptor (IR). IR then phosphorylates insulin receptor substrate (IRS). The activation of IRS 
activates two signaling pathways. The first is the phosphatidylinositol 3- kinase (PI3K) – 
AKT/ protein kinase B (PKB) pathway that is related to the metabolic actions of insulin. More 
specifically, the phosphorylation of IRS activates PI3K, which in turn activates a second 
messenger, phosphatidylinositol-(3,4,5)-triphosphate, which subsequently activates several 
phosphatidylinositol-(3,4,5)-triphosphate-dependent serine/threonine kinases, including 
AKT/PKB. The last one activates the translocation of glucose transporter 4 to the plasma 
membrane, which increases the glucose uptake (Saltiel and Kahn, 2001).  The second 
signaling pathway that is affected by IRS activation is the Ras-mitogen-activated protein 
kinase (MAPK) pathway that is related to the mitogenic and growth effects of insulin. The 
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MAPK pathway leads to the activation of genes that promote cell growth, inflammation and 
atherosclerosis (Jung and Choi, 2014). 
FFAs and their metabolites, such as acyl-coenzyme A (acyl-CoA), ceramides and 
diacylglycerol (DAG) can impair insulin signaling. These enzymes can activate several 
serine/threonine kinases, such as protein kinase C (PKC), inhibitory kinase kB (IKKβ) and 
nuclear factor kappa B (NF-kB) (Schinner et al., 2005). PKC, IKKβ, NF-kB etc. can also be 
activated by inflammatory molecules such as tumor necrosis factor α (TNF-α) and 
interleukin-6 (IL-6) (Delarue and Magnan, 2007). The activation of these kinases leads to the 
inactivation or inhibition of the key proteins of the insulin pathway. Additionally inhibition of 
insulin-stimulated IRS-1 (Insulin receptor substrate 1) phosphorylation (Petersen and 
Shulman, 2006) can lead to less GLUT4 translocation and finally lower glucose uptake 
(Figure 1). 
 
Figure 1.  Schematic view of insulin pathways and inhibition by FFAs. Insulin binds to the insulin receptor. 
Then the insulin receptor phosphorylates the insulin receptor substrate (IRS) which in turn activates PI3K. Next 
PI3K activates PKB/AKT through the PIP2 and PIP3. Finally GLUT4 translocation is established and glucose 
uptake takes place. Parallel IRS activates MAPK through the activations of SOS/Ras and MEK. On the other 
hand FFA and its metabolites can inhibit insulin action by inhibition of insulin-stimulated IRS phosphorylation 
or inhibiting PKB/AKT with the PKD, IKKβ and NF-kB.  PI3K, phosphatidylinositol 3 kinase; PKB/AKT, 
protein kinase B; GLUT-4, glucose transporter type 4; FFA, free fatty acids; DAG, diacylglycerol; ROS, reactive 
oxygen species; IKKβ, inhibitory kB kinase β; NF-kB, nuclear factor kB. Based on Delarue and Magnan (2007) 
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Adipose tissue function 
Adipose tissue plays a major role in the energy storage of the body and in energy 
homeostasis. In addition, adipose tissue is nowadays considered to be an endocrine organ that 
synthesizes and secretes biologically active substances (Ahima and Flier, 2000; Kershaw and 
Flier, 2004; Galic et al., 2010; Boden 2011). Adipose tissue consists of different kind of cells 
including adipocytes, preadipocytes, endothelial cells and immune cells such as macrophages 
(Jung and Choi, 2014). The energy in the adipose tissue is stored in adipocytes in the form of 
triglycerides. When there is a surplus of triglycerides then adipocytes either increase in 
numbers (hyperplasia) or increase in size (hypertrophy) (Hausman et al., 2001). Enlargement 
of adipocytes is related with increased lipolysis, which is associated with T2DM (Engfeldt 
and Amer, 1988; Weyer et al., 2000). In case of energy need the triglycerides are lipolysed 
and release free fatty acids (FFAs) into the systemic circulation. FFAs are then transported to 
the organs and tissues in need of energy. Increased levels of FFAs, in obesity for example, can 
cause dysfunctions and dysregulations. The FFAs can directly enter the liver and increase 
lipid synthesis and gluconeogenesis and increase hepatic insulin resistance (Boden, 1997). 
The FFAs can cause insulin resistance in the peripheral organs (Boden, 1997; Kelley et al., 
1993). The FFAs can also trigger cytokine production of immune cells since they are ligands 
of the Toll-like receptor 4 (TLR-4) (Shi et al., 2006). By activating TLR-4, inflammation is 
induced which is characterized as a major contributor to obesity-associated metabolic 
complications (Suganami et al., 2005). 
Dyslipidemia 
A relationship between obesity and dyslipidemia with T2DM was observed by Sam and 
Haffner (Sam et al., 2008). Dyslipidemia is the state at which increased levels of lipids 
circulate in the blood (Clemente-Postigo et al., 2011). Obesity related dyslipidemia includes 
high levels of plasma FFAs, low levels of high density lipoprotein (HDL) and abnormal 
composition of low-density lipoprotein (LDL). This situation occurs when adipose tissue 
releases increased number of FFAs, through lipolysis. Increased levels of FFAs can decrease 
the mRNA expression and/or activity of lipoprotein lipase (LPL) (Klop et al., 2013). In 
addition to the decreased activity of LPL, there is also increased very-low-density-lipoprotein 
synthesis (VLDL). High levels of VLDL produced in the liver can inhibit the lipolysis of the 
chylomicrons, leading to hypertriglyceridemia (Jung and Choi, 2014). Consequently, 
hypertriglyceridemia promotes cholesteryl ester transfer protein-mediated exchange of 
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triglycerides for cholesterol esters between triglyceride-rich lipoproteins such as (VLDL) and 
lipoproteins, which leads to a decreased HDL-cholesterol concentration and a low number of 
triglycerides in LDL (Klop et al., 2013). Increased number of triglycerides in LDL are 
hydrolyzed by hepatic lipase (HL), promoting small dense LDL formation that is associated 
with higher risk of cardiovascular disease and T2DM (Guendouzi et al., 1999; St Pierre et al., 
2005; Mooradian 2008; Rizzo et al., 2009). 
Obesity induced inflammation 
As an endocrine organ, the adipose tissue, in the obese state (Figure 2), secrets various 
chemokines and cytokines, such as monocyte chemotactic protein 1 (MCP-1), tumor necrosis 
factor alpha (TNF-), interleukin 1 (IL-1), interleukin 6 (IL-6) and interleukin 8 (IL-8) that 
promote insulin resistance (Hotamisligil, et al., 1993; Jung and Choi, 2014; Amrani et al., 
1996; Sartipy and Loskutoff 2003; Rotter et al., 2003). Additionally, the macrophages of the 
adipose tissue change phenotypically and switch from an anti-inflammatory M2 polarization 
state to a pro-inflammatory M1 polarization state (Lumeng et al., 2007; Jung and Choi, 2014). 
Consequently, secretion of pro-inflammatory chemokines and cytokines takes place, which is 
linked to insulin resistance (Jiao et al., 2009). Conclusively, a decreased number of 
macrophages that infiltrate adipose tissue is correlated with insulin sensitivity (Jung and Choi, 
2014).  
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Figure 2. Adipose tissue in normal and obese subjects. In obese state there is an increase in the size of 
adipocytes and increase of FFAs and pro-inflammatory adipokine secretion. As a consequence there are 
modifications in inflammatory, glucose and lipid responses. Conversely the levels of anti-inflammatory 
adipokines are decreased. Additionally a switch in the macrophages phenotype is forced from M2 polarization to 
M1 polarization. Based on Jung and Choi (2014) 
Toll-like receptor 4 (TLR-4) 
Toll-like receptor 4 (TLR-4) was the first characterized mammalian Toll receptor of the Toll-
like receptor family, which plays a significant role in the innate immune system acting against 
microbial pathogens and inducing adaptive immune responses (Medzhitov, 1997; Kawai and 
Akira 2006; Medzhitov, 2001). It has been reported that TLR-4 detects lipopolysaccharide 
(LPS) as the ligand and upon ligand binding acts as a signal-transducing receptor (Poltorak et 
al., 1998, Qureshi et al., 1999; Hoshino et al., 1999; Baccala et al., 2007; Tarkowski et al., 
2010). After recognition of LPS, a cascade of signals starts in two pathways (Figure 3). The 
first is the Myeloid Differentiation primary response gene 88 pathway (MyD88) at which 
TLR-4 binds to the MyD88 at the TIR (Toll/Interleukin-1 receptor), the cytoplasmic domain 
of TLR-4. Then the amino-terminal of MyD88 interacts with the amino-terminal of IRAK 
(IL-1R-associated kinase). Next the formed MyD88-IRAK interacts with TOLLIP (Toll-
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interacting protein). IRAK is autophosphorylated and it is able to connect with TRAF-6 
(TNF-receptor associated factor 6) (Doyle and O’Neil 2006; Medazhitov, 2001; Zangh and 
Ghosh, 2001). This activates Tat-associated kinase (TAK) and Mitogen activated protein 
kinase kinase (MKK6) which in turn phosphorylates the IkB kinase (IKK) complex. 
Subsequently NF-kB and c-Jun N-terminal kinases (JNK) are finally activated (Baccala et al., 
2007; Kim 2006; Kawai and Akira, 2006; Medzhitov, 2001; Shi et al., 2006; Tarkowski et al., 
2009; Tschopp et al., 2003). Parallel to this pathway TLR-4 has another pathway, the MyD88-
independent pathway that is based in the connection of TLR-4 to the TIR domain of TIRAP 
(domain-contain adapter protein) (Kawai and Akira, 2006; Medzhiton, 2001; Mogensen, 
2009). TIRAP signals through RNA-dependent protein kinase (PKR) and interferon 
regulatory factor 3 (Cohen 2002) which later activate NF-kB. NF-kB activation is linked with 
insulin resistance, T2DM and inflammation (Arkan et al., 2005). Tarkowski and his 
colleagues showed (2010) that resistin, a cytokine, is competing with LPS for TLR-4 binding. 
 
Figure 3. Schematic representation of TLR-4 pathways. The MyD88 pathway follows the activation of IRAK, 
TRAF and IKK. The MyD88 independent pathway follows the activation of PKR and/or IRF3. Both pathways 
lead to the activation of NF-kB. Based on Cohen (2002) 
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Resistin 
Resistin is a 12.5kDa polypeptide, which belongs to the cysteine-rich proteins termed resistin 
like molecules (RELMs) (Patel D et al., 2004). In rodents it is secreted by white adipose 
tissue (McTernan et al., 2002) and in humans basically by adipocytes and macrophages (Patel 
L et al., 2003). In hyperglycemic and hyperinsulinemic rodents and in humans with T2DM it 
has been reported that resistin appears in increased levels in plasma (Hartman et al., 2002; 
Lazar, 2007; Rajala et al., 2004; Stofkova, 2010). The actual receptor of resistin is still 
unknown. However, several possible pre-diabetic effects of resistin have been reported 
(Stofkova, 2010). First, resistin could inhibit the intrinsic activity of cell surface glucose 
transporters as for example the insulin-stimulated 2-deoxyglucose which contributes to 
glucose uptake (Moon et al., 2003). Second, resistin could suppress GLUT4 translocation 
(Palanivel et al., 2006) or its gene expression resulting the reduction of insulin capability for 
glucose uptake (Fu et al., 2006). Third, resistin could promote SOCS-3 expression, which is a 
known insulin resistance promotor, thus inhibiting insulin signaling (Steppan et al., 2005). 
Fourth, resistin could block insulin transduction pathways such as PI-3k/Akt (Sheng et al., 
2008) as it is shown in figure 1. Fifth, resistin could promote the expression of gluconeogenic 
enzymes and hinder AMPK activity, correspondingly stimulating the hepatic glucose 
production (Banerjee et al., 2004). Finally, resistin could activate the release of FFAs from 
adipose tissue (Pravenec et al., 2006). 
PPARγ – TZDs 
Until recently medication for T2DM was focused on the use of peroxisome proliferator-
activated receptor gamma (PPARγ) agonists. Specific ligands for PPARγ are 
thiazolidinediones (TZDs) (Berger et al., 2002; Yki-Jarvinen, 2004). However, only 
pioglitazone has remained in use after troglitazone and rosiglitazone were withdrawn from the 
market because of hepatotoxicity and increased risk of heart attacks, respectively. In some 
countries even pioglitazone has been withdrawn from the market because of its possible 
association with increased incidence of bladder tumors. PPARγ (Figure 4) is a receptor that 
regulates adipogenesis and glucose homeostasis (Tontonoz and Spiegelman, 2008). As 
mentioned before dysregulation of these two functions can cause insulin resistance. PPARγ 
has the ability to promote lipid uptake and storage by the adipose tissue. Uptake of lipids by 
the peripheral organs would promote insulin resistance (Barnes and Miner, 2009; Boden et al., 
2005). Additionally, activation of PPARγ by TZDs in rodents and humans increased the 
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insulin-stimulated glucose uptake thereby counteracting the effects in T2DM (Yki-Jarvinen, 
2004). Furthermore, in vitro research in mice has shown that PPARγ activation by various 
TZDs is correlated with the minimum effective dose (MED) for their antihyperglycemic 
activity (Willson et al., 1996). The insulin sensitizing effects of TZDs could be related to the 
binding and activation of the PPARγ receptor. In addition, PPARγ activation has been 
correlated to the downregulation of adipokines, such as resistin which promote inflammation 
and eventually lead to insulin resistance. 
 
Figure 4. PPARγ activation by TZDs modulates glucose and lipid metabolism, leading to improved insulin 
sensitivity. Activation of PPARγ increases lipid uptake and storage. Activation of PPARγ also increases the 
production of anti-inflammatory adipokines, such as adiponectin, and decreases the production pro-inflammatory 
adipokines such as resistin, TNF-alpha and MCP-1. Additionally PPARγ forces macrophages towards anti-
inflammatory M2 phenotype, reducing the macrophage infiltration into fat. Based on Tontonoz and Spiegelman 
(2008) 
Other possible targets for drug development 
More recently due to the side effects resulting in the withdrawal of the majority of the TZDs 
from the market, research has been redirected away from PPARγ and the TZDs focusing on 
other possible targets for drug development. These include in addition to resistin, already 
described above and the major focus of the present thesis, incretin hormone glucagon-like 
peptide 1 receptor (GLP-1R) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-
glucose cotransporter type 2 (SGLT-2) inhibitors. The first two are focusing on targeting the 
“incretin effect”, which is the glucose-dependent increase of insulin stimulation in response to 
nutrients, in comparison with the glucose infused intravenously, and is decreased in T2DM 
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(Holst and Orskov 2004; Nauck 2016; Lutz and Osto 2016). More specifically GLP-1 is a gut 
hormone and has been found to stimulate insulin secretion. DPP-4 is responsible for the 
degradation and inactivation of incretin hormones. Therefore finding GLP-1 agonists and/or 
DPP-4 inhibitors might be of use in finding targets for drug development for T2DM (Graaf et 
al. 2016). Examples of GLP-1R agonists are exenatide, liraglutide, lixisenatide, dulaglutide 
and albiglutide (Nauck 2016). Examples of DPP-4 inhibitors are sigagliptin, saxagliptin, 
linagliptin and alogliptin (Nauck 2016). On the other hand inhibition of SGLT-2, which is 
involved in glucose reabsorption in the blood after it is filtered by the kidney, uses a more 
hemodynamic approach, since it is targeting the kidney so as to increase urinary glucose 
excretion (Reed 2016; Scheen 2016). Examples of SGLT-2 inhibitors are canagliflozin, 
dapaglifloxin and empagliflozin. 
Outline of the thesis 
Type 2 Diabetes Mellitus (T2DM) is a modern metabolic disorderand results when the body is 
unable to produce sufficient amount of insulin or does not respond properly to insulin, the 
hormone that regulates the level of glucose in blood (Saltiel et al., 2001). The increase of 
glucose in the blood may cause hyperglycemia that leads to long term complications. On the 
other hand, a decrease of glucose levels may cause hypoglycemia that might lead to coma and 
ultimately to death (Guo et al., 2009). 
T2DM is the most common type and is a result of impaired activity of β-cells, which are the 
cells that produce insulin, in combination with the insulin resistance of the insulin-targeted 
organs. It is closely related with the metabolic syndrome which is described by abdominal 
obesity, atherogenic dyslipidemia, elevated blood pressure, insulin resistance and 
prothrombotic and proinflammatory states (Tenenbaum et al., 2003). Until now, there are no 
easy medical treatments for diabetes. Additionally, the treatments do not have a preventive 
character for the complications associated with diabetes, such as neuropathy, retinopathy and 
nephropathy (Segev et al., 2003). Usually medical treatments focus on the use of exogenous 
insulin to control the level of glucose or on the transplantation of the whole-pancreas organ 
which has been the most effective treatment for diabetic people with severe complications, 
until now (Bonner-Weir et al., 2005). One of the major drawbacks is the limited supply of 
donor tissues (Weir et al., 1997). 
The aim of the present thesis was to define novel targets for the possible development of 
drugs for T2DM. Optimization of present preventive therapies including development of less 
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expensive drugs may be of help. Such new drugs may be analogues to presently prescribed 
drugs like for example pioglitazone and rosiglitazone which belong to the thiazolidinedione 
class of insulin sensitizing compounds that act as PPARγ agonists, and have an important role 
in lipid metabolism and insulin sensitization. The structure activity relationship between 
PPARγ agonists and their glucose lowering activity has been well established (Willson et al., 
1996). However given the serious side effects there is a need for definition of other targets for 
development of drugs for T2DM. Amongst possible novel targets, adipokines such as resistin 
that promote insulin resistance have been identified as possible novel targets for development 
of drugs for T2DM, since resistin has been reported to be detected at higher levels in plasma 
of T2DM patients (Owecki et al., 2011) and has also been reported to be downregulated upon 
PPARγ activation (Saltiel et al., 2001). Thus, the aim of the present thesis was to define novel 
targets for the possible development of drugs for T2DM with emphasis on resistin related 
mechanisms. 
Chapter one of the thesis gives an introduction and a global overview of T2DM, insulin 
function and the adipose tissue as well as of the modes of action underlying the adverse 
effects in T2DM. T2DM results from impaired insulin production of the β-cells of the 
pancreas and from the inability of the peripheral organs targeted by insulin to exert adequate 
glucose uptake from the blood, leading to insulin resistance. In this thesis we focused 
especially on resistin as a possible new drug strategy and novel drug target that deals with 
insulin resistance. 
Given that PPARγ activation is an important target for TZDs, drugs that were withdrawn for 
too serious side effects but were effective against T2DM, in chapter 2 we investigated 
whether for a series of related TZDs the level of activation of PPARγ detected by a CALUX 
reporter gene assay would correlate with their potential for resistin downregulation in mouse 
adipocytes, and whether the EC50s for resistin downregulation in the mouse adipocytes would 
correlate with the MED reported for their antihyperglycemic activity in a mouse model 
(Willson et al., 1996). If such correlations would be established it would support the use of 
resistin downregulation as an additional and possibly more direct target for the development 
of antihyperglycemic compounds.  
Given that resistin may be an important new target for development of drugs for T2DM and 
that the TLR-4 receptor may be an important target for resistin mediated induction of 
biological effects, in chapter 3 we investigated the possible use of a TLR-4 signaling reporter 
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gene cell line to detect antagonists for resistin mediated effects. Studies have shown that 
resistin competes with LPS for TLR-4 binding (Tarkowsky, 2010). Consequently, the 
inhibition of resistin induced TLR-4 signaling could provide a new mechanism and screening 
tool to detect and develop new T2DM drugs able to counteract resistin induced insulin 
resistance. 
Resistin is proven to promote insulin resistance with a possible intermediate role for the TLR-
4 receptor although the actual receptor(s) of resistin and the actual pathway(s) that resistin 
uses are still unknown. In chapter 4 we investigated the effects of resistin in human 
adipocytes. We used an RNA sequencing method to obtain detailed insight in the effects of 
resistin in adipocytes and possibly identify novel biomarkers that could be useful for the 
development of new T2DM medicines.  
In chapter 5 we used a novel in vitro model for T2DM, combining adipocytes with activated 
macrophages. This assay was used to screen for new proteins that could be involved in 
T2DM. The aim was to identify novel protein markers that can be of interests for research into 
the mechanism of T2DM development and additional risk assessment of obese patients prior 
to the onset of T2DM. In addition, our data were compared to in vivo data sets from mice and 
humans to further investigate whether some of these proteins have the potential to be used as 
diagnostic tools/biomarkers which would allow for a better and more personalized treatment 
of T2DM patients. 
Finally in chapter 6 a general discussion is presented with remarks about the findings in this 
thesis and some future perspectives about the methods used but also for the general problem 
of T2DM. 
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Abstract  
The present study shows significant correlations between the EC50 for PPARγ activation in a 
reporter gene cell line and resistin downregulation in mouse adipocytes, and between the IC50 
for resistin downregulation and the already published minimum effective dose for 
antihyperglycemic activity in a mouse model. These correlations indicate that PPAR 
mediated downregulation of resistin might promote insulin sensitivity and that 
downregulation of resistin in mouse adipocytes provides an adequate and possibly more direct  
bioassay for screening of newly developed antihyperglycemic compounds. Because of the 
higher throughput of the PPARγ the resistin downregulation assays seems most suitable to be 
used as a second tier in a tiered screening strategy. 
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Introduction  
Insulin resistance is the state at which the insulin targeted organs are not responding to insulin 
signaling (Lazar, 2007). It is a characteristic feature of human and rodent obesity and type 2 
diabetes mellitus (Ferrannini, 1992). The mechanism underlying insulin resistance is poorly 
understood, but the phenomenon is strongly associated with increased adipogenesis and 
increased serum levels of free fatty acids (Boden, 1997; Lazar, 2007; Reitman et al., 2000). 
Excessive deposition of fat not only in adipocytes but also in peripheral organs, such as 
skeletal muscles and liver, can lead to insulin resistance (Tarcin et al., 2007). Consequently 
medication that reduces or eliminates insulin resistance is needed for the prevention or the 
treatment of type 2 diabetes mellitus. 
Current drug development strategies for type 2 diabetes focus on the development of 
peroxisome proliferator-activated receptor gamma (PPARγ) agonists. Thiazolidinediones 
(TZDs) are an example of such insulin sensitizing compounds that are ligand specific to 
PPARγ (Berger and Moller, 2002; Yki-Jarvinen, 2004). Currently only pioglitazone is used as 
medication, after the withdrawal of troglitazone in 2004 and rosiglitazone in 2011 from the 
market because of suspected hepatotoxicity and increased risk of heart attacks, respectively.   
Studies have shown that the effect the TZDs have on insulin resistance is related to the 
activation of PPARγ in their primary target tissue being the adipose tissue (Lehrke and Lazar, 
2005). PPARγ is a receptor that regulates adipogenesis and glucose homeostasis (Tontonoz 
and Spiegelman, 2008). Several studies have shown that poor functioning of adipogenesis and 
glucose homeostasis can lead to insulin resistance. Activation of PPARγ promotes the uptake 
of lipids in the adipose tissue and not in peripheral organs such as the liver and muscle. 
Uptake of the lipids in peripheral organs reflects the insulin resistant state (Barnes and Miner, 
2009; Boden et al., 2005). Additionally activation of PPARγ is correlated with the production 
of smaller more insulin-sensitive adipocytes (Okuno et al., 1998). Treatment with the TZDs 
rosiglitazone, pioglitazone and troglitazone increased the insulin-stimulated glucose uptake in 
peripheral organs in rodents and in human (Yki-Jarvinen, 2004).  Willson and his colleagues 
(Willson et al., 1996) have shown that for a series of structurally related TZDs their EC50 for 
PPARγ activation detected in an in vitro reporter gene assay could be correlated to the 
minimum effective dose (MED) for their antihyperglycemic activity characterised in an in 
vivo mouse model.  
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Thus, the biological effects of the TZDs on insulin sensitivity have been ascribed to their 
binding to and activation of PPARγ that might be involved in the insulin sensitizing effects of 
TZDs (Tontonoz and Spiegelman, 2008). A possible central downstream mechanism for the 
insulin sensitizing effects of TZDs is the modulation of bioactive molecules such as 
adipokines (Tontonoz and Spiegelman, 2008). Activation of PPARγ, resulting downregulation 
of the adipokine resistin, has been suggested to be involved in the mechanism underlying the 
insulin sensitising effect of TZDs (Tontonoz and Spiegelman, 2008). 
Resistin is a 12.5 kDa polypeptide, belonging to the family of cysteine-rich proteins termed 
RELMs (Resistin-Like Molecules) (Patel D. et al., 2004). It is secreted by the white adipose 
tissue in mice (McTernan P. et al., 2002) and by adipose tissue and macrophages in humans 
(Patel L et al., 2003). Increased levels of resistin in hyperglycemic and hyperinsulinemic 
rodents and in obese and type 2 diabetes mellitus human have been reported (Hartman et al., 
2002; Lazar, 2007; Rajala et al., 2004; Stofkova, 2010). Upon PPARγ activation by the TZD 
rosiglitazone, resistin was reported to be downregulated (Saltiel and Kahn, 2001; Steppan et 
al., 2001).  It has been suggested that resistin is involved in insulin resistance by interfering 
with the insulin signaling pathway, however its receptor causing the downstream effects on 
insulin sensitivity remains to be established (Barnes and Miner, 2009; Daquinag et al., 2011; 
Haugen et al., 2001; McTernan P. et al., 2003; Sanchez-Solana et al., 2012; Tarkowski et al., 
2010). The aim of the present study was to investigate whether for a series of related TZDs 
the level of activation of PPARγ detected by a recently developed reporter gene assay would 
correlate with their potential for resistin downregulation in mouse adipocytes, and whether the 
EC50s for resistin downregulation in the mouse adipocytes would correlate with the MED 
reported for their antihyperglycemic activity in a mouse model (Willson et al., 1996). If such 
correlations would be established it would support the use of resistin downregulation as an 
additional and possibly more direct target for the development of antihyperglycemic 
compounds.  
Materials and methods 
Thiazolidinediones 
The structures of the TZDs that were used in this study are shown in Figure 1. Rosiglitazone 
(CAS Nr: 122320-73-4), CAY-10415 (CAS Nr: 146062-49-9), CAY-10506 (CAS Nr: 
292615-75-9), ciglitazone (CAS no. 74772-77-3), pioglitazone (CAS no. 111025-46-8) were 
purchased from Cayman chemicals (Ann Arbor, Michigan). DRF-2519 (CAS Nr: 194713-46-
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7) was purchased from Sigma (St. Louis, USA). 5,4-Fluorobenzilidene-2,4-TZD (CAS Nr: 
262601-87-6) was purchased from Santa Cruz Chemicals (California, USA). Englitazone 
(CAS Nr: 122228-35-7) was purchased from Dalton Chemicals Services (Toronto, Canada). 
CS-7017 (CAS Nr : 223132-38-5) (Shimazaki et al., 2008), BRL-48482 (Buckle et al., 1996; 
Imran et al., 2007), DRF-2189 (CAS Nr : 172647-53-9) (Lohray et al., 1998), (Z)-5-[[4-[2-(2-
Benzoxazolylmethylamino) ethoxy]phenyl]-methylene]-2,4-thiazolidinedione (Cantello et al., 
1994) (from now on called 65 as in the reference), (Z)-5-[[4-[2-(Methyl-2-
pyridinylamino)ethoxy]phenyl]-methylene]-2,4-thiazolidinedione (Cantello et al., 1994) 
(from now on called 66 as in the reference) and PMT-13 (Chakrabarti et al., 2002; Imran et 
al., 2007) were synthesized by Chiralix (Nijmegen, Netherlands) according to literature 
(Buckle et al.,1996; Cantello et al., 1994; Chakrabarti et al., 2002; Lohray et al., 1998; 
McTernan P. et al., 2003) and the purity and identity of the compounds was confirmed by 
1
H-
nuclear magnetic resonance spectroscopy (
1
H-NMR) performed on a Varian 400 MHz 
spectrometer (Palo Alto, California) and compared to data reported in literature (Buckle et al., 
1996; Cantello et al., 1994; Chakrabarti et al., 2002; Lohray et al., 1998; McTernan P. et al., 
2003). All compounds were tested for cytotoxicity using the MTT test performed as described 
previously (Hussain et. al., 1993). 
 
Figure 1. Chemical structure of TZDs tested for PPAR-γ activation and resistin downregulation 
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Reporter gene cell line and assay 
The cell line that was used for this study is a CALUX reporter gene cell line consisting of 
U2OS cells stably transfected with a 6xPPREtataLuc construct and an expression vector 
specific for PPARγ2 described in detail elsewhere (Gijsbers et al., 2011). Cells of this 
PPARγ2 CALUX reporter cell line were cultured in Dulbecco’s modified Eagle’s medium 
and Ham’s F12 medium (DMEM with high glucose and l-glutamine)(Glutamax, Invitrogen, 
Breda, Netherlands) supplemented with 7.5% Fetal Calf Serum (FCS, Invitrogen), 1% Non-
Essential Amino acid (NEAA, Invitrogen) and 0.1% penicillin/streptomycin (10u/ml-
10μg/ml, Invitrogen). Once per week, 200 μg/ml G418 was added to the culture medium in 
order to keep selection pressure on the cells. 
On the first day cells were trypsinised and diluted in assay medium (DMEM: F12 without 
phenol red), supplemented with 5% stripped serum (DCC FCS), 1% NEAA 100x and 0.1% 
penicilium/streptomycin and plated in a 96 well plate at 10000 cells/well. On the second day 
cells were exposed to TZDs at concentrations of 100 pM up to 10 μM for 24h with the 
exception of DRF-2189 that was tested at concentrations of 1nM up to 10 μM. On the third 
day, cells were lysed and luciferase activity was measured as described before (Gijsbers et al., 
2011). To this end 100 μl of Flash Mix (20 mM tricine, 1.07 mM (MgCO3)4Mg(OH)2 5H2O, 
2.67 mM MgSO4, 0.1 mM EDTA, 2.0 mM dithiothreitol, 470 μM D-luciferine, and 5.0 mM 
ATP) were added per well and light production was measured directly using a luminometer 
(Anthos, Eugendorf, Austria) and expressed as relative light units (RLUs). 
3T3-L1  preadipocytes 
3T3-L1 fibroblast-like preadipocytes were cultured in DMEM with high glucose and l-
glutamine, supplemented with 10% Newborn Calf Serum (NCS, Thermo Fisher Scientific - 
Rockford, Illinois) and 1% penicillin/streptomycin/ampicilin (Sigma, St.Louis, Missouri) and 
incubated at 37
o
C at 5% CO2. The cells were split 1:10 twice every week. The confluence 
during culturing was kept below 80%.  
Differentiation to adipocytes 
For the differentiation of pre-adipocytes into adipocytes, 16000 3T3-L1 cells per well were 
seeded in 6-well plates and incubated until confluence. After 2 days of confluence the cells 
were ready for differentiation. The medium was changed to MDI (methylxanthine – 
dexamethasone – insulin) induction medium being DMEM with high glucose and l-glutamine 
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supplemented with 10 % FCS, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.5 μg/ml 
insulin, 0.1 μM dexamethasone on day 0 and incubated for 3 days. After three days, the MDI 
induction medium was changed to insulin medium (Insulin medium being DMEM high 
glucose and l-glutamine supplemented with 10% FCS, 0.5μg/ml insulin) and incubated for 3 
days. On day 6, the medium was changed to DMEM high glucose and l-glutamine 
supplemented with 10% FCS. Full differentiation as judged by morphological changes and 
red oil O staining occurred 9 days after changing to MDI induction medium (see Result 
section). 
mRNA isolation 
Upon changing the medium to MDI induction medium, samples were taken each day to 
measure resistin mRNA expression during differentiation until day 9. Additionally, the cells 
were exposed to series of TZDs on day 7 for 24h. For mRNA isolation the medium was 
aspired and cells were washed with PBS. Then 600 μl of 1% β-mercaptoethanol in RLT lysis 
buffer (Qiagen kit) were added, cells were scraped and the lysate was collected and stored at -
80
o
C until further analysis. 
The purification of RNA was done using the RNeasy mini kit obtained from QIAGEN 
(Venlo, Netherlands). For the homogenisation of the lysate, a QIAshredder spin column was 
used (Qiagen, Venlo, Netherlands). In brief the lysate (600 μl) was transferred onto a 
QIAshredder spin column and centrifuged at 14000 rpm for 2 minutes. Then 600 μl of 70% 
ethanol were added to the flow through of the spin column and the sample was mixed 
thoroughly. Part of lysate/ethanol mixture was transferred to an RNeasy column and 
centrifuged at 14000 rpm for 15 sec. The flow through was discarded. The rest of the 
lysate/ethanol mixture were added to the same RNeasy column and centrifuged at 14000 rpm 
for 15 sec. The flow through was discarded. Next RW1 buffer was added to the column and 
the column was centrifuged at 14000 rpm for 15s and the flow through was discarded. Next 
500 μl of RPE buffer was added to the column and the column was centrifuged at 14000 rpm 
for 15s and the flow through was discarded. The step was repeated one more time with 2 min 
of centrifugation. The column was transferred to a new tube and RNase-free water (30 μl) was 
added, followed by centrifugation at 14000 rpm for 15s to elute total RNA. The concentration 
of total RNA that was collected in the flow through was measured with a Nanodrop (ND-
1000, Thermo scientific, Wilmington, Delaware). 
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Reverse Transcriptase reaction and Real-Time PCR with SYBR green 
To perform the reverse transcriptase (RT) reaction an Omniscript RT kit (Qiagen, Venlo, 
Netherlands) was used. Total RNA samples were diluted to 0.33 μg/μl in RNase-free water. 
To each sample 2 μl 10x buffer RT, 2 μl dNTP Mix, 2 μl Random Hexamer Primers, 2.5 μl 
RNase Inhibiter, 1 μl Omniscript Reverse Transcriptase and 4.5 μl of RNase-free water were 
added and the mixture was incubated for 60 minutes at 37
o
C in an iCycler (Bio-Rad) to obtain 
cDNA.  
The expression of resistin mRNA was measured by real-time quantitative chain polymerase 
reaction (RT-qPCR) using an iCycler (Bio-Rad). For every reaction 5 μl of sample cDNA, 1 
μl forward (CTGTGTCCCATCGATGAAGC), 1 μl reverse (CTCAAGACTGCTGTGCC 
TTC) primers specific for mouse resistin, 12.5 μl of Sybr green mastermix (Bio-Rad) and 5.5 
μl of RNase free water were used. The plate was incubated at 95oC for 15 min, and then for 
45 cycles each consisting of incubation at 95
o
C for 30 sec, at 60
o
C for 30 sec, at 72
o
C for 45 
sec. This was followed by incubation at 72
o
C for 5 min, at 95
o
C for 1 min and finally 10 sec 
for every half degree from 95
o
C to 55
o
C for the melting curve. Hypoxanthine-guanine 
phosphoribosyltransferase (Hprt) quantitect primer assay by Qiagen was used as invariant 
endogenous control. 
Data analysis 
For the data analysis GraphPad Prism software was used (version 5.00 for windows, 
GraphPad software, San Diego, USA). The gene expression of resistin was measured with 
real time PCR. Relative quantification was performed according to the comparative 2
-ΔΔCt 
method (Pfaffl, 2001). The relative expression was normalized with the Hprt gene, which was 
taken as a housekeeping gene. The ΔΔCt calculation was used as follows ΔΔCt = (Ct, target 
gene – Ct, Hprt) – (Ctc, target gene – Ctc, Hprt), with Ct being the number of threshold cycles 
of the target gene and Ctc being the number of threshold cycles of the control, in this case the 
unexposed cell sample. The results for the gene expression was given as a unitless value 
through the formula 2
-ΔΔCt
 (Pfaffl, 2001). For the PPARγ activation and the inhibition of 
resistin mRNA expression, dose-response curves of the data were used to determine the EC50 
and the IC50 values respectively. The correlation between PPARγ EC50 values and resistin 
IC50 values between resistin IC50 and MED values was determined by calculating the linear 
regression (R
2
) and the correlation coefficient (Pearson r).  
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Results 
Synthesis of TZD model compounds 
Although several TZDs could be commercially obtained many additional TZD model 
compounds had to be synthesized. The compounds CS-7017, BRL-48482, DRF-2189, 65, 66 
and PMT-13 were synthesized according to literature (Buckle et al., 1996; Cantello et al., 
1994; Chakrabarti et al., 2002; Lohray et al., 1998; McTernan P. et al., 2003). Purity and 
identity of the synthetized compounds were analysed by 
1
H-NMR. Spectral data were 
identical to the data reported in literature (Buckle et al., 1996; Cantello et al., 1994; 
Chakrabarti et al., 2002; Lohray et al., 1998; McTernan P. et al., 2003). 
PPAR activation by the TZD model compounds in the PPARγ-2 CALUX stable 
reporter cell line 
For the determination of PPARγ activation by the ligand specific TZDs the recently 
developed PPARγ-2 CALUX cell line (Gijsbers et al., 2011) was used. Figure 2 shows the 
dose-dependent luciferase induction in the assay upon exposure of the cells to increasing 
concentrations of four representative TZDs. The results are expressed as percentage of the 
positive control, rosiglitazone, measured as relative light units (RLUs). The different TZDs 
show different potencies for PPARγ mediated induction of luciferase activity. From the dose 
dependent curves using the GraphPad software, the EC50 values for the PPARγ induction by 
the different TZDs were determined (Table 1). These results reveal that CS-7017 showed the 
highest potency, reflected by an EC50 value that was 20 fold lower than that for rosiglitazone. 
CAY-10506 and BRL-48482 were also more potent than rosiglitazone with EC50 values that 
were respectively 2.3 and 1.3 fold lower than that of rosiglitazone. PMT-13, DRF-2519, 65, 
66, CAY-10415, DRF-2189, 5-(4-fluorobenzilidine)-2,4-TZD and englitazone showed 1-500 
fold lower potency than rosiglitazone (Table 1). 
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Figure 2. Dose dependent PPARγ activation by four representative TZDs including CS-7017 (A), BRL-48482 
(B) and PMT-13 (C), and DRF-2519 (D) expressed as % of the maximum rosiglitazone response (rosiglitazone, 
dotted line) which is included for comparison, measured as relative light units. 
Table 1. EC50 values of PPARγ activation as tested in this study and in literature, IC50 values of resistin mRNA 
inhibition in μM calculated using Graphpad software v.5 and minimum effective dose (MED) in vivo from 
literature. 
Thiazolidinedione EC50 (μM) IC50 (μM) EC50 (μM)  
Literature 
MED (μmol kg-1 ) 
Englitazone 13.39 - 13 - 
DRF-2519 0.435 1.07 - - 
CAY-10506 0.0106 0.0585 10 - 
CAY-10415 4.88 0.198 - - 
65 0.0786 0.187 0.14 300 
66 0.342 0.0521 0.19 300 
5-(4-
fluorobenzylidine) 
-2,4-TZD 
11.9 - - - 
DRF-2189 0.798 2.28 - - 
PMT-13 0.0314 0.00584 0.01 - 
CS-7017 0.00132 0.000595 0.0002 - 
BRL-48482 0.0178 0.00246 0.013 3 
Rosiglitazone 0.024 0.0262 0.01 3 
Ciglitazone - 7.553 3 3000 
Pioglitazone 0.60 4.59 0.69 300 
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Optimization of the 3T3-L1 adipocytes differentiation 
Figure 3 shows the morphology of the 3T3-L1 preadipocytes during the differentiation 
process to adipocytes followed by microscopy. Changes in the morphology of the cells started 
at day 3. Lipid droplets started to be formed after day 6 and full maturation to adipocytes was 
achieved at day 9. For the sample at day 9 the presence of lipid droplets was confirmed by 
staining with Red Oil O which is a lipid specific stain (Figure 3E). Figure 4 shows the resistin 
mRNA detected in the cells from day 0 to 9 during the differentiation of pre-adipocytes to 
adipocytes. From these data it follows that resistin mRNA levels increase upon increased 
differentiation of the cells with levels increased from day 7 onwards. Based on these results it 
was decided to expose the cells to the various TZDs from day 7 to 8 and detect possible 
effects on resistin expression levels at day 8. 
 
Figure 4. Resistin mRNA expression during differentiation from day 0 to day 9 expressed as log(2
-ΔΔCt
), 
normalized with undifferentiated cells of day 0. 
Resistin downregulation by the TZD model compounds in 3T3-L1 adipocytes 
Figure 5 shows the dose dependent change of resistin gene expression as quantified by qPCR 
after the exposure of the cells to a series of TZDs. From the results presented, it follows that 
resistin gene expression is inhibited by TZDs. The IC50 values for the TZD mediated resistin 
downregulation in the 3T3-L1 adipocytes were derived from these dose-dependent curves 
using the Graphpad software and are shown in Table 1. The TZDs clearly differed in their 
potency for resistin downregulation in the 3L3-L1 adipocytes. CS-7017 showed the highest 
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Figure 3. Microscopic pictures of 3T3-L1 cells differentiating into mature adipocytes at day 0 (A), day 3 (B), 
day 6 (C) and day 9 (D) during differentiation. The presence of lipids on day 9 was confirmed by the Oil Red O 
staining (E). 
potency for inhibiting resistin gene expression reflected by an IC50 that was 44 fold lower than 
that obtained for rosiglitazone, a known inhibitor of resistin gene expression. BRL-48482, 
PMT-13, were also more potent than rosiglitazone with IC50 values that were respectively 10 
and 4.5 fold lower than that of rosiglitazone. CAY-10415, CAY-10506, 65, 66, DRF-2519 
and DRF-2189 showed 2-80 fold lower potency than rosiglitazone. Englitazone and 5-(4-
fluorobenzilidene)-2,4-TZD were not able to inhibit resistin gene expression in the 3T3-L1 
adipocytes.  Using the MTT assay it was established that at the concentrations tested the 
TZDs did not affect cell viability. 
Figure 6 shows the correlation between the calculated EC50 values for PPARγ activation in 
the reporter gene assay and the IC50 values for resistin downregulation in the mouse 
adipocytes. A significant correlation (p<0.05) of R
2 
= 0.693 is obtained. The Pearson 
correlation coefficient amounts to r=0.832. Figure 7 shows the correlation between the 
calculated IC50 value for resistin downregulation and the MED for the antihyperglycemic 
activity in vivo of six TZDs for which these MED data were available (Willson et al., 1996). 
The correlation between resistin downregulation and the MED for antihyperglycemic activity 
revealed an R
2
=0.71 (p<0.05) and a Pearson correlation coefficient of r=0.877. 
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Figure 5. Inhibition of resistin mRNA expression in 3T3-L1 mouse adipocytes by four representative TZDs, CS-
7017 (A), BRL-48482 (B) PMT-13 (C) and DRF-2519 (D) expressed as unitless value from the formula of 2-
ΔΔCT. All figures also present the curve for rosiglitazone (dotted line) used as the reference compound. The 
experiment was repeated 3 times. 
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Figure 6. Correlation between EC50 values for PPARγ activation in a reporter gene assay and IC50 values for 
inhibition of resistin expression in mouse adipocytes. A significant correlation of R
2
=0.693 with p<0.05 was 
obtained. The Pearson correlation coefficient was calculated r=0.832. 
 
Figure 7. Correlation between IC50 for downregulation of resistin in mouse adipocytes and the minimum 
effective dose (MED) for antihyperglycemic activity found in vivo in a mouse model (Willson et al., 1996). A 
significant correlation of R
2
=0.71 with p<0.05 was obtained. The Pearson correlation coefficient was calculated 
r=0.877. 
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Discussion 
The aim of the present study was to investigate whether resistin downregulation in mouse 
3T3-L1 adipocytes could provide a suitable endpoint for testing new antihyperglycemic 
drugs, as an alternative for PPARγ agonist activity. To this end it was investigated if for a 
series of related TZDs the EC50 for activation of PPARγ detected in a recently developed 
reporter gene assay would correlate with their potential for resistin downregulation in mouse 
adipocytes, and subsequently if the IC50 values for resistin downregulation would correlate 
with the MED for antihyperglycemic activity in a mouse model reported in the literature 
(Willson et al., 1996). 
For fourteen TZDs their potency to activate PPARγ in the PPARγ-2 CALUX assay and their 
potency to down regulate resistin in 3T3-L1 adipocytes was quantified. The EC50 values for 
PPAR mediated gene expression obtained using the newly developed PPARγ-2 stable 
reporter cell line were comparable to the EC50 values reported in the literature for PPARγ 
agonist activity of some the TZDs using other PPARγ reporter gene assays (Imran et al., 
2007; Willson et al., 1996). The only difference between the data previously reported and 
those obtained in the present study were the results obtained for CAY-10506 that showed a 
1000 fold lower EC50 value in the present study than reported in literature. 
Rosiglitazone is a known inhibitor of resistin gene expression (Daquinag et al., 2011; Haugen 
et al., 2001; Rajala et al., 2003) and the results of the present study reveal that also other 
TZDs can reduce resistin expression levels. The TZDs differ in their potency to inhibit resistin 
gene expression in the mouse adipocytes.  
A comparison between the EC50 values for PPARγ activation and the IC50 values for resistin 
downregulation revealed a significant correlation (p <0.05) of R
2
=0.693 (Figure 6). The 
calculated correlation coefficient showed a Pearson r of 0.832. This correlation between EC50 
for PPARγ agonist activity and the IC50 for resistin dowregulation may reflect that the resistin 
downregulation is PPARγ mediated. This would be in line with the findings of Steppan et al. 
(2001) who reported that resistin is downregulated by the TZDs upon PPARγ activation. 
In a subsequent analysis a direct comparison between the IC50 for inhibition of resistin 
expression and the MED for antihyperglycemic activity of a series of six TZDs in a mouse 
model (Willson et al., 1996) was performed. This comparison also revealed, a significant 
correlation as shown in Figure 7 (R
2
=0.71, p<0.05). The correlation coefficient showed a 
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Pearson r of 0.877 (p<0.05). These correlations indicate that PPAR mediated downregulation 
of resistin might inhibit its negative effects and promote insulin sensitivity, and that 
downregulation of resistin in mouse adipocytes provides an adequate bioassay, in addition to 
PPARγ activation, for the screening of newly developed antihyperglycemic compounds.  
Because of the higher throughput of the PPARγ the resistin downregulation assays seems 
most suitable to be used as a second tier in a tiered screening strategy. 
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Abstract 
The present study investigated whether a reporter assay detecting Toll-like receptor 4 (TRL-4) 
mediated gene expression could be a possible bioassay to detect candidate drugs able to 
inhibit resistin mediated effects. This was done because inhibition of resistin mediated 
activities may prove a novel target for development of antidiabetic drugs. To detect activation 
of TLR-4 mediated gene expression and enable detection of possible antagonists for resistin 
mediated activation of the receptor, a TLR-4 reporter gene cell line (HEK-Blue-TLR-4) was 
applied. The results obtained reveal that resistin, like the natural ligand lipopolysaccharide 
(LPS) is able to activate TLR-4 mediated gene expression with EC50 values for LPS and 
resistin amounting to respectively 0.05 μg/ml and 5 μg/ml. Resistin was also shown to 
compete with LPS for binding to TLR-4.  The LPS or resistin dependent induction of TLR-4 
mediated gene expression was inhibited by two known TLR-4 inhibitors including, LPS-RS 
and Polymyxin B. It is concluded that the TLR-4 reporter gene cell line provides a novel tool 
to detect resistin antagonists and may be of use as a new target to screen for a possible new 
type of antidiabetic drugs. 
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Introduction 
The causes of Type 2 diabetes mellitus (T2DM) are impaired insulin production and the 
inability of insulin sensitive organs to take up glucose, a state that is called insulin resistance. 
Insulin resistance has been correlated with inflammation (Boden, 1997; Lazar, 2007). Several 
inflammatory and proinflammatory factors, including resistin, have been identified in obese 
patients with T2DM (Spanger et al., 2003; Pradhan et al., 2001; Nagaev et al., 2006; Schwartz 
et al., 2011). Current drugs for the treatment of T2DM mainly originate from the group of 
thiazolidinediones, and extensive drug development programmes focusing on activation of 
PPARγ mediated gene expression as an important characteristic of the thiazolidinediones 
(Willson et al., 1996) have been or are being executed. In the search for additional and 
alternative targets for treatment of T2DM the hormone resistin has been identified.  
Resistin has been associated with the pathogenesis of obesity which is directly connected to 
T2DM (Lazar et al., 2007; Owecki et al., 2011; Benomar et al., 2016). Resistin is a 12.5 kDa 
polypeptide and belongs to the resistin-like molecule hormone family (Steppan et.al., 2001, 
Patel et al., 2004). In rodents and humans, high levels of resistin are correlated with obesity 
and impaired insulin resistance (Stappan et al., 2001; Owecki et al., 2011). Consequently 
inhibition of resistin activity using anti-resistin antibodies was shown to improve insulin 
sensitivity and glucose homeostasis (Steppan et. al., 2001). Nonetheless the receptor 
mediating these downstream effects on insulin sensitivity is not yet identified (Barnes and 
Miner, 2009; Daquinag et al., 2011; Haugen et al., 2001; McTernan P. et al., 2003; Sanchez-
Solana et al., 2012; Tarkowski et al., 2010). 
It has been shown that resistin can be a ligand towards the Toll-like receptor 4 (TLR-4) and 
that resistin is able to compete with the natural ligand, which is lipopolysaccharide (LPS), for 
binding to the TLR-4 (Poltorak et al., 1998; Qureshi et al., 1999; Hoshino et al., 1999; 
Tarkowski et al., 2010).  In these studies antibodies against TLR-4 abolished resistin binding 
to human leucocytes and inhibited cytokine production by peripheral blood mononuclear cells 
in response to resistin stimulation (Tarkowski et al., 2010). Activation of the TLR-4 receptor 
was also shown to play a significant role in the activity of the innate immune system against 
microbial pathogens and in the induction of adaptive immune responses (Kawai and Akira, 
2006; Medzhitov, 2001). It was also shown that TLR-4 detects lipopolysaccharide (LPS) 
(Tarkowski et al., 2010). Additionally insulin sensitivity was shown to be suppressed by 
resistin following its binding to TLR-4 (Benomar et al., 2012). Resistin signals were shown to 
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lead to the activation of pro-inflammatory pathways and the induction of insulin resistance 
through the regulation of several mediators, such as adaptor protein MyD88, Toll/interleukin-
1 receptor domain-containing adaptor proteins (TIRAP), Jun NH2-terminal kinase (JNK) and 
p38 mitogen activated protein kinase (MAPK) (Benomar et al., 2012). More recent studies on 
TLR-4 knockout mice and neuronal cells expressing TLR-4 siRNAs showed no effects of 
resistin and revealed a novel mechanism of insulin resistance caused by central resistin-TLR-
4 pathway where adiponectin is inhibited promoting FGF21 resistance (Benomar et al., 2016) 
All the above point at a possible role of resistin mediated activation of TLR-4 in the activation 
of inflammatory pathways and the induction of insulin resistance, important responses in 
T2DM. Given the possible role of resistin mediated activation of TLR-4 in these T2DM 
related responses it would be of interest to develop a method to detect possible inhibition of 
resistin induced inflammation and insulin resistance through TLR-4 as a novel target in drug 
development. Such an assay would allow identification of resistin induced TLR-4 signaling 
antagonists and or inhibitors that could be considered as possible novel compounds for 
treatment and or prevention of T2DM. The aim of the present study was to investigate if the 
TLR-4 reporter gene cell line (HEK-Blue-TLR-4) can be used to detect resistin mediated 
activation of TLR-4 as well as its inhibition by possible antagonists and or inhibitors. To this 
end we tested the activity of LPS, a natural ligand for TLR-4, and resistin in this TLR-4 
reporter gene cell line. We also investigated whether the assay could detect inhibition of LPS 
or resistin mediated activation of TLR-4 by two known inhibitors of TLR-4 signaling. 
Materials and methods 
Inhibitors and resistin 
Two known, commercially available, inhibitors of TLR-4, LPS-RS and Polymyxin B were 
purchased from InvivoGen (Toulouse, France). Human resistin was purchased from Bio-
connect B.V. (Huissen, Netherlands). 
HEK-Blue-TLR-4 cells. 
The reporter gene cell line HEK-Blue-TLR4 was purchased from InvivoGen (Toulouse, 
France). According to the manufacturer these cells are designed to study human TLR-4 
activation by monitoring the activation of NF-κΒ. More specifically this cell line was 
generated by transfecting the hTLR-4 gene, the MD-2/CD14 co-receptor genes and a secreted 
embryonic alkaline phosphatase (SEAP) reporter gene into HEK293 cells. The SEAP reporter 
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gene was placed under the control of an IL-20 p40 minimal promoter fused to five NF-κB and 
AP-1 binding sites. Consequently any stimulation with TLR-4 ligand would activate NF-κB 
and AP-1 which would induce the production of SEAP (HEK-Blue™ hTLR4, InvivoGen). 
Furthermore SEAP levels were detected with QUANTI-Blue™ (InvivoGen) which is an 
alkaline phosphatase detection medium. 
Reporter gene assay 
Briefly, cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 4.5 g/l glucose, 10% fetal calf serum (FCS, Invitrogen), 50 U/ml penicillin 
(Invitrogen), 50 μg/ml streptomycin (Invitrogen), 100 μg/ml Normocin™ (InvivoGen) and 2 
mM L-glutamine (Gibco by life technologies, Netherlands). The growth medium was renewed 
2 times per week. Cells were not cultured above 20 passages according to manufacturer’s 
directions. 
For testing the compounds 200 μl of a cell suspension were plated in 96 well plates at a 
concentration of 1.4x10
5
 cells/ml. The medium that was used for the testing was 
supplemented with heat inactivated (56 
o
C for 30 min) FCS. TLR-4 signaling was induced 
according to the protocol provided by the supplier by exposing the cells first to LPS (0.05 
μg/ml). Simultaneously the exposed cells were exposed to the two TLR-4 inhibitors at final 
concentrations varying from 3 ng/ml to 10 μg/ml for LPS-RS and 10ng/ml to 70 μg/ml for 
polymyxin b to inhibit the LPS induced signaling. Plates were incubated at 37 
o
C in 5% CO2 
for 22 h. Similarly, TLR-4 signaling was induced by exposing cells to resistin (5 μg/ml) and 
then simultaneously cells were exposed to the two inhibitors in concentrations ranged as 
mentioned above. 
Quanti-Blue™ colorimetric enzyme activity assay 
For the detection of the activity of the reporter gene SEAP, 180 μl per well Quanti-BlueTM and 
20 μl of the supernatant of the exposed cells were incubated for 2 h at 37 oC with 5% CO2. 
The SEAP activity was measured by measuring the formation of the blue reaction product 
using a spectrophotometer (Molecular Device, USA) at 620 nm.  
MTT assay 
The MTT assay was used to test if there was a possible cytotoxic effect of the compounds at 
the concentrations tested. In brief, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) diluted in PBS were added to the HEK-Blue-TLR4 cells 
exposed to the TLR-4 inhibitors at the same concentrations as in the inhibition experiments. 
Plates were incubated for 22 h at 37 
o
C with 5% CO2. Then medium was removed and 100 μl 
DMSO (Merck, Germany) were added to lyse the cells and dissolve the formazan crystals. 
Plates were shaken for 15 min to allow the blue/violate formazan crystals to dissolve. The OD 
was measured at 562 nm and 620 nm. The results were expressed as percentage of the lowest 
concentration. 
All experiments were performed in triplicate and data are expressed as the percentage of the 
lowest concentrations of the average of three experiments. IC50 values were determined   
using the Graphpad Prism 5 software. The software uses a non-linear regression fit described 
by the equation: 
Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)) 
Results 
Resistin induces TLR-4 signaling in HEK-blue TLR-4 cells 
The first step was to verify resistin’s TLR-4 inducing ability in HEK-blue TLR-4 cells and 
compare it with the induction by LPS, the natural ligand of TLR-4. Figures 1A and 1B show 
the LPS induced TLR-4 signaling and resistin induced TLR-4 signaling. From these data it 
can be derived that both compounds are able to induce TLR-4 mediated gene expression with 
the EC50 of LPS being 0.05 μg/ml and 100 fold lower that the EC50 of resistin which 
amounted to 5 μg/ml.   
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Figure 1. LPS induced TLR-4 signaling by LPS (A) and resistin (B). 
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Viability of the cells upon exposure to the TRL-4 inhibitors  
In a next step it was investigated whether the TRL-4 inhibitors to be tested would affect 
viability of the HEK-Blue-TLR4 cells. This was done to enable selection of non-cytotoxic 
concentrations to be tested in the TLR-4 reporter gene assay and/or correct for cytotoxicity if 
needed. From these data it can be derived that LPS-RS and Polymyxin B did not affect cell 
viability up to the highest concentrations tested (Figures 2A, 2B). This can be taken into 
account when analyzing results from the reporter gene assay. 
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Cell viability of HEK-Blue-hTLR4 afte exposure to Polymyxin B
-3 -2 -1 0 1 2
0
50
100
150
Concentration μg/ml (log10)
C
e
ll
 v
ia
b
il
it
y
 (
P
e
rc
e
n
ta
g
e
 o
f 
th
e
 p
o
s
it
iv
e
 c
o
n
tr
o
l)
B 
Figure 2 Viability of HEK-Blue-TLR4 cells when exposed to increasing concentrations of  LPS-RS (A) and 
Polymyxin B (B). 
Effect of TLR-4 inhibitors on LPS and resistin induced TLR-4 signaling.   
We used two known inhibitors for the determination of the inhibition of LPS induced TLR-4 
signaling. The results are shown in figures 3A, 3B and IC50 values derived from these graphs 
are summarized in table 1. The levels of TLR-4 signaling inhibition by the two compounds 
are expressed compared to the value at the lowest concentration of inhibitor set to 100%. In 
figure 2A inhibition of LPS by LPS-RS is shown. The IC50 for inhibition of LPS induced 
TLR-4 gene expression was 0.2 μg/ml (R2=0.9259). Polymyxin B (Figure 2b) inhibited the 
LPS induced TLR-4 mediated gene expression with an IC50 value of 5.7 μg/ml (R
2
=0.99). 
Together these data reveal that the TLR-4 reporter gene assays can be used to detect TRL-4 
antagonism towards LPS. 
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Inhibition of LPS induced TLR-4 signalling by LPS-RS
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Inhibition of LPS induced TLR-4 signalling by Polymyxin B
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Figure 3. Inhibition of LPS induced TLR-4 signaling by LPS-RS (A) and polymyxin B (B). The concentration 
of LPS present in the respective incubations amounted to its EC50 value of 0.05 μg/ml for activation as 
determined from Figure 1A. IC50 values were calculated by Graphpad prism and amounted to 0.2 μg/ml and 5.7 
μg/ml respectively 
Figures 4A and 4B show the inhibition of the resistin induced TLR-4 mediated gene 
expression by LPS-RS and Polymyxin B respectively when TLR-4 signaling is induced by 
resistin. LPS-RS inhibited the resistin-induced TLR-4 signaling with an IC50 of 0.29 μg/ml 
(R
2
=0.7). Polymyxin B inhibited the signaling with an IC50 of 7.2 μg/ml (R
2
=0.64). These 
data reveal that the TRL-4 reporter gene assay could also detect TRL-4 antagonism with 
respect to resistin as the agonist.  
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Figure 4. Inhibition of resistin induced TLR-4 signaling by LPS-RS (A) and resistin (B). The concentration of 
resistin present in the respective incubations amounted to its EC50 value of 5 μg/ml for activation as determined 
from Figure 1B. IC50 values were calculated by Graphpad prism and amounted to 0.29 μg/ml and 7.2 μg/ml 
respectively 
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Table 1. IC50 values for TLR-4 inhibition by LPS and resistin as determined from the curves presented in figures 
3 and 4 
 LPS Resistin Literature IC50 
LPS Resistin 
 IC50 R
2
 IC50 R
2
 - - 
LPS-RS 0.2μg/ml 0.93 0.29μg/ml 0.7 0.1 μg/ml 
(Lu et. al. 2013) 
- 
Polymyxin B 5.7μg/ml 0.99 7.2 μg/ml 0.64 1.6 μg/ml 
 (Khownium et. al. 
2005) 
- 
Discussion 
The aim of the present study was to investigate whether a reporter gene assay for Toll-like 
receptor 4 (TLR-4) signaling could be used as a method for detecting resistin antagonism. 
Given the role of resistin in increasing insulin resistance this may provide a novel target for 
development of novel drug strategies for T2DM. The connection of resistin with the TLR-4 
receptor was made initially by Tarkowski et al. (2010) who reported that resistin competed 
with LPS for the binding to TLR-4. Taking this into consideration we used a commercially 
available reporter gene cell line to investigate whether this assay would enable detection of 
resistin antagonism. Both LPS and resistin were shown to act as agonists able to induce TLR-
4 mediated gene expression in the reporter gene with EC50 values of 0.05 μg/ml and 5 μg/ml 
respectively. Stevens et al. (2013) showed a range of EC50 for LPS induced TLR-4 mediated 
gene expression from 3 experiments of 0.011 to 0.084 μg/ml which complies with our results. 
As for resistin mediated activation of TLR-4 this study is to the best of our knowledge, the 
first one reporting an EC50 value for this interaction. In several cell based models with 
different cell lines (THP-1, PBMC) resistin effect concentrations have been reported, ranging 
from 50 ng/ml to 1000 ng/ml (Tarkowski et al., 2010; Benomar et al., 2012; Lee et al., 2012). 
Only in one of these studies an EC50 for a resistin induced effect was presented representing 
an EC50 for induction of growth hormone release, but not for TLR-4. EC50s were obtained for 
dispersed anterior pituitary cells exposed to resistin (Rodríguez-Pacheco et. al., 2009) for 4 
and 24 hours and amounted to 3.5 nM and 2.6 pM respectively. Normally serum resistin in 
humans ranges from 7 to 22 ng/ml but is significantly increased in patients with T2DM 
(Jamaluddin et al., 2011; Steppan et al., 2001). It is also increased in patients with metabolic 
syndrome and its related diseases such as coronary artery disease and cardiovascular disease 
(Ohmori et al., 2005; Reilly et al., 2005). In a study with patients with acute coronary 
syndrome serum resistin levels reported as high as 1.18 μg/ml (Wang et al., 2009). 
Nonetheless there are differences in the quantitative observations reported by different groups 
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a phenomenon most probably reflecting resistin’s secretion timing (McTernan et al., 2003; 
Jamaluddin et al., 2011).  
In a next step the inhibition of the LPS induced TLR-4 mediated gene expression by selected 
inhibitors was characterized. For LPS-RS it has been reported that it inhibits LPS mediated 
effects by competing with LPS for the same binding site on MD-2 (Golenblock et al., 1991; 
Coats et al., 2005). Polymyxin b has been reported as an endotoxin binding protein able to 
inhibit LPS mediated effects by binding to lipid A, the toxic component of LPS (Duff et al., 
1982; Shoenfelt et al., 2009; Birknmeier et al., 2006; Bhor et al., 2005). The results obtained 
in the present study revealed that both inhibitors were able to reduce the LPS mediated TLR-4 
gene expression in the reporter gene assay with IC50 values of 0.2 μg/ml and 5.73 μg/ml for 
LPS-RS and polymixin b respectively. Lu et al. reported an IC50 of LPS-RS for LPS 
inhibition at 0.1μg/ml which is close to our results. Khownium et al. (2005) showed an IC50 
for polymyxin B inhibition of LPS induced TLR-4 mediated effects of 1.6 μg/ml.  
In a next step we tested if these inhibitors would also inhibit resistin induced TLR-4 signaling. 
Both compounds showed resistin antagonism, inhibiting resistin mediated TLR-4 induced 
gene expression. Comparison of the IC50s for inhibition of the LPS and resistin induced TLR-
4 signaling reveals that the IC50s for LPS-RS and also for Polymyxin B are quite close 
differing less than 2-fold.  
Based on the results obtained it can be concluded that the HEK-Blue-hTLR4 cell line which is 
commercially available can be used to screen for compounds that may inhibit resistin induced 
TLR-4 signaling, reflecting resistin antagonism. Given the role of resistin in increasing insulin 
resistance in T2DM (Benomar et al., 2012; Benomar et al., 2016) this assay may proof of 
value as a novel target in high throughput screening of compounds that could counteract 
insulin resistance via resistin antagonism. Whether this will eventually lead to novel classes of 
drugs for T2DM remains to be established. 
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Abstract 
Resistin is a small cysteine-rich protein hormone involved in inflammation and insulin 
resistance. Resistin is mainly secreted from adipose tissue in mice and from immune and 
epithelial cells but also from adipocytes in humans. An increase in obesity and insulin 
resistance was observed to be correlated with increased levels of resistin. The precise mode of 
action of resistin is however still unclear. To better understand the cellular processes that are 
altered by resistin, we profiled human omental adipocytes, with and without resistin 
treatment, by means of next generation sequencing (RNA-sequencing) to determine the 
resistin specific modulation of gene expression. In total, 55 genes were significantly up or 
down regulated under the influence of resistin in human omental adipocytes.  Pathway 
analysis with Ingenuity Pathway Analysis showed basically 2 networks that are affected by 
the identified genes. These two networks are “protein trafficking, cellular assembly and 
organization and cellular function and maintenance” and “cell death and survival, cancer 
and organismal injury and abnormalities”. An analysis of the specific function of the genes 
up and down regulated with regards to the two networks mentioned indicate that resistin is 
involved in modifications in transcriptional regulation processes with a role in cellular 
differentiation and maintenance processes. From the gene expression data it can be proposed 
that resistin is a survival regulator and is involved in lipid storage. Resistin appears to be 
expressed when energy conservation is essential. When energy conservation is accompanied 
by food overconsumption, obesity, inflammation and insulin resitance can be the 
consequence. Resistin can therefore be considered as a biomarker protein for these health 
related issues. 
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Introduction 
In 2014, the WHO, estimated the number of diabetic people at 422 million, compared to 108 
million in 1980. Obesity is one of the main factors contributing to type 2 diabetes mellitus 
(T2DM), but it is also linked to insulin resistance, cardiovascular diseases and cancer 
(Benomar et al., 2012, Caballero, 2003; Calle et al., 2003). In 2014, 1.9 billion adults were 
overweight and 600 million were obese (WHO, 2015; Cabia et al., 2016). Obesity is 
characterized by the excessively storage of body fat in adipose tissue, leading to a chronic 
inflammatory state (Sousa-Santos et. al., 2013; Lumeng and Saltiel, 2011; Freitas-Lima et. al., 
2015). Adipose tissue operates as an endocrine organ (Cabia et al., 2016) that secretes 
adipocytokines such as leptin, adiponectin, resistin and IL-6 (Wang et. al., 2004; Galic et al., 
2010). These adipocytokines play a major role in energy homeostasis and metabolism. In 
obese persons, changes occur in the secretion of these inflammatory cytokines, which can 
affect insulin sensitivity through effects on the energy homeostasis (Kahn and Flier, 2000; 
Wellen and Hotamisligil, 2003; Steppan et al., 2001; Olefsky and Class, 2009). 
Resistin is a 12.5 kDa hormone that is mainly secreted by adipocytes in mice, while in 
humans immune and epithelial cells but also adipocytes can secrete resistin (McTernan et al., 
2002; Cabia et a., 2016). The expression in human adipose tissue is suggested to originate 
from resident inflammatory cells (Schwartz and Lazar, 2011; Patel et al., 2003; McTernan et 
al., 2002), but adipocytes can also contribute to resistin expression (McTernan et al., 2002; 
Benomar et al., 2012; Reilly et al., 2005; Silha et al., 2003; Vendrell et al. 2004).  Resistin has 
6 disulfide bonds, which suggests that the protein is very stable in an in vivo situation as 
degradation by proteases will be hampered by the compact global inert structure (Patel et al., 
2004).  
In this study we investigated the mechanism behind resistin mediated effects by exposing 
human adipocytes to resistin and analyzing its effect on gene expression. We identified genes 
that were up or down regulated by resistin in human adipocytes using RNA sequencing 
technology (RNAseq). 
Materials and methods 
Human omental adipocytes 
Human omental adipocytes (Omental Adipocytes 96-Well PlateSuperlot, mixed donor 
lot)(Zen-bio, NC, USA) were used for this study. The cells were from a female non-diabetic, 
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non-smoking individual with BMI of 45.84 and age 34.6. Those cells were already 
differentiated and delivered in a multiwell plate, so no (sub)culturing had to be done. Every 3-
4 days the medium was refreshed with Omental Basal Medium (OM-BM) (Tebu-bio, 
Netherlands) supplemented with 1x penstrep. 
Exposure of cells to resistin and RNAseq sampling 
Regarding the RNAseq sampling cells were treated as follows. Human omental adipocytes 
were maintained according to manufacturer's protocol. Medium was removed from the wells 
and the cells were washed one time with Phosphate Buffered Saline (PBS)(Gibco, Paisley, 
Scotland), Netherlands). OM-BM was added containing either 1 μM human resistin (Sigma-
Aldrich, St. MO, USA) or no resistin (control). Cells were treated for 18 hours and 
subsequently harvested in Qiazol (Qiagen, Venlo, NL).  
rRNA removal with ribo-zero removal kit.  
In more detail, magnetic beads had to be washed before using them. Therefore magnetic 
beads were added to an eppendorf tube and washed, pelleted, re-suspended in storage buffer 
and until used in room temperature and the tube was placed on a magnetic stand for 1 min. 
Remaining beads were stored at 2 
o
C to 8 
o
C. In a separate eppendorf tube total RNA isolated 
from the adipocytes was treated with rRNA removal solution provided by the manufacturer. 
Treated sample was incubated and rRNA probes hybridize to rRNA. 
Ribo-zero removal kit – preparation of magnetic beads.  
For each sample, 225 μl of the Magnetic Beads were transferred into an RNase-free tube 
slowly avoiding bubble formation. Tubes were placed on a magnetic stand for 1 min until the 
solutions became clear. Then supernatant was removed. Tubes were removed from the 
magnetic stand, and 225 μl of RNase-Free Water were added after which the magnetic beads 
were resuspended by vortexing for 3 times. Tubes were then replaced on the magnetic stand 
for 1 min until the solutions became clear again after which the remaining water was 
discarded. Next 65 μl of Magnetic Bead Resuspension Solution were added and the beads 
were resuspended by vortexing once. 
Ribo-zero rRNA removal kit – preparation of samples.  
In an RNase-free microcentrifuge tube 20 μl of total RNA, 8 μl of RNase-free water, 8 μl of 
rRNA removal solution (containing probes that hybridizes to rRNA) and 4 μl of rRNA 
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reaction buffer were added. The solution was mixed thoroughly and incubated for 10 min at 
68 
o
C. Any condensation left was removed and the solution was incubated at room 
temperature for 5 min. 
For each sample 40 μl of probe-hybridized RNA sample were transferred to the 65 μl of 
washed, room temperature Magnetic Beads. Immediately and thoroughly the contents were 
mixed by pipetting 10–15 times. Additionally tubes were vortexed at high speed for a 
minimum of 10 sec and incubated for 5 min at room temperature. After this, the tubes were 
incubated at 50 
o
 C for 5 minutes. After this incubation the tubes were placed on a magnetic 
stand for at least 1 minute until the solutions became clear. The supernatant containing the 
sample depleted of rRNA was removed, and transferred to an appropriately sized RNase-free 
microcentrifuge tube in -20 
o
C. 
Ethanol precipitation of the rRNA-depleted sample. 
The volume of each rRNA-depleted sample was adjusted to 180 μl using RNase-Free Water. 
18 μl of 3 M sodium acetate and 2 μl of glycogen (10 mg/ml) were added to each tube, 
followed by gentle vortexing. Additionally 3 volumes (600 μl) of ice-cold 100% ethanol were 
added and the samples were vortexed gently. Tubes were placed at -20 °C for at least 1 hour. 
Subsequently the samples were centrifuged at 10,000 x g for 30 minutes and the supernatants 
were carefully removed and discarded. The pellets were washed with ice-cold 70% ethanol 
and centrifuged at higher than 10,000×g for 5 minutes. The supernatants were removed and 
discarded. This washing step with ethanol was repeated twice with 70% ethanol. 
Centrifugation was repeated to collect and remove any residual supernatant. The final pellets 
containing rRNA-depleted RNA were air dried at room temperature for 5 min. The rRNA-
depleted RNA pellets were dissolved in 10 μl of RNase-Free Water and samples were stored 
in -20 
o
C overnight. 
ScriptSeq RNA-seq library preparation kit - cDNA synthesis 
For the fragmentation of RNA we used in a total of 12 μl, 1 μl fragmentation solution, 2 μl 
cDNA Primer and 9 μl of dissolved rRNA-depleted RNA incubated for 5 min at 85 oC in a 
thermocycler with heated lid. RNA fragmentation was stopped by placing the sample on ice. 
The next step was the synthesis of cDNA. To this end to each sample were added 4 μl of 
cDNA synthesis master mix (3 μl of cDNA synthesis, 0.5 μl of 100mM DTT and 0.5 μl of 
StarScript AMV Reverse Transcriptase). Incubation at 25 
o 
C for 5 min was followed by 
Chapter 4 
64 
 
incubations at 42 
o
C for 20 min.  Then the reactions were cooled to 37 
o
C. One by one the 
reactions were taken out from the thermocycler and 1μl of Finishing Solution was added. 
Incubation at 37 °C for 10 minutes followed. After this incubation, each sample was 
incubated at 95 
o
C for 3 min and finally cooled to 25 
oC. For the tagging of DNA 8 μl of 
Terminal Tagging Master Mix (7.5 μl of Terminal Tagging Premix and 0.5 μl of DNA 
Polymerase) were added to each sample followed by thorough mixing and incubation first at 
25 
o
C for 15 min and then at 95 
o
C for 3 min. Finally the reactions were cooled to 4 
o
C. 
For PCR amplification the cDNA was purified. To this end the MinElute PCR purification Kit 
(Qiagen, Venlo, NL) was used. According to the manufacturer 5 volumes of Buffer PB were 
added to 1 volume of the PCR reaction and mixed thoroughly. MinElute columns were placed 
in collection tubes provided by the manufacturer. Samples were applied to the MinElute 
columns and centrifuged for 1 min. The flow-through was discarded. For the washing, 750 μl 
of PE buffer were put to the columns and centrifuged for 1 min. To completely remove 
ethanol from PE buffer the columns were additionally centrifuged for 1 min at maximum 
speed. Afterwards columns were put in clean tubes. To elute DNA, 10 μl EB buffer were 
added in the center of the membrane, let for 1 min and the samples were centrifuged for 1 
min. 
The samples were sent to ServiceXS (Leiden, Netherlands) and sequenced with an Illumina 
Hi-Seq instrument. Single 50 nt reads were aligned to hg19 genome assembly by TopHat and 
analysed by SAMtools and BAMtools. The analysis of the RNA-seq was processed in 
R/Bioconductor with the program DESeq (standard settings) to identify the differentially 
expressed genes, as well as generating the volcano plot. 
Pathway analysis with Ingenuity Pathway Analysis software 
The results of RNAseq gene expression data expressed as a ratio of resistin exposed 
adipocytes   versus unexposed adipocytes along with the gene IDs  with the concomitant p-
values were uploaded to Ingenuity Pathway Analysis (IPA).  In IPA the information uploaded 
is matched to databases (based on an indepth analysis of biological literature). IPA generates 
algorithmically biological networks and defines canonical pathways and functions related to 
the genes uploaded. Each network acquires a score that indicates the possibility that the 
identified genes within the network are clustered together with focus genes that are from the 
uploaded list, pass filters that are applied, and are available for generating networks 
(http://www.ingenuity.com).  
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Results 
The exposure of adipocytes to resistin modulated significantly the expression of 55 genes. In 
table 1 the genes that were significantly differentially expressed after resistin exposure with 
the respective log2 fold change and p-value are shown. The log2 difference shows the effect 
of the presence as compared to the absence of resistin, while the p-value of 0.05 was applied 
to rule out effects that are purely random. 
Table 1. Significantly up or down regulated genes after exposure of human adipocytes to resistin followed by 
the p-value. Inf stands for infinite log2 change indicating the absence of the gene in one of the two samples. 
Upregulated p-value Log2 change Downregulated p-value Log2 change 
FLJ45340 7.43e-21 7.199672 SNRPD2 3.44e-14 -3.05784 
SIX4 9.36e-12 5.178914 KCTD7 2.07e-13 -6.28716 
ZNF138 6.16e-11 6.894818 HYAL3 1.28e-12 -6.18133 
UFM-1 4.37e-11 6.083479 SETD4 9.35e-09 -Inf 
CNTFR 3.64e-08 4.988685 LOC100133161 5.99e-08 -Inf 
C11orf10 1.84e-08 3.269259 DQ596074 5.88e-07 -Inf 
DQ598070 8.01e-07 Inf DQ592203 3.37e-07 -Inf 
ISY1 4.34e-07 Inf SNORD25 3.08e-07 -Inf 
AK023614 1.94e-07 Inf JA429802 8.37e-06 -1.954 
C19orf42 7.89e-06 Inf CHURC1-FNTB 6.91e-06 -Inf 
MIR4731 3.41e-06 Inf C4orf43 3.81e-06 -4.28011 
SNORD113-1 3.41e-06 Inf CNP 1.73e-06 -3.63176 
MIR4800 1.21e-06 Inf DQ595216 9.89e-05 -Inf 
LPL 7.89e-05 2.134426 U42379 7.32e-05 -Inf 
SNORD114-9 7.89e-05 2.134426 DQ786325 6.69e-05 -3.67646 
MIR611 5.42e-05 Inf ZFP161 4.75e-05 -3.84472 
MIR125B1 5.15e-05 3.839776 C15orf38 1.12e-05 -Inf 
IFIT5 4.30e-05 2.138414 DQ576933 0.000302 -Inf 
DM074112 2.83e-05 Inf DQ588370 0.000302 -Inf 
FU270179 2.83e-05 Inf JA535805 0.000181 -Inf 
FU270191 2.83e-05 Inf ZNF846 0.000109 -Inf 
TIMM8A 2.83e-05 Inf FLJ27352 0.000125 -2.54785 
MIR1206 1.49e-05 Inf    
DQ595173 0.000313 Inf    
MIR181A1 0.000313 Inf    
SNORD115-5 0.000313 Inf    
AF047486 0.000263 2.383704    
DQ596932 0.000251 Inf    
DQ598479 0.000251 Inf    
CPEB3_ribozyme 0.000201 Inf    
SNORD1A 0.000166 2.222392    
DQ574699 0.00016 2.818582    
SNORD114-3 0.000129 2.971331    
 
FLJ45340 showed the most significant upregulation with 7.199 log 2 fold change with a p-
value of 7.43e-21. SIX4, ZNF138, UFM1, CNTFR, C11orf10 DQ59870 and ISY1 followed. 
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Among the genes that were significantly upregulated were also a number of micro RNAs 
(miRNAs) (MIR4800, MIR4731, MIR2016, MIR611, MIR181A1, MIR125B1), small 
nucleolar RNAs (snoRNA) (SNORD113-1, SNORD115-5, SNORD114-3, SNORD1A, 
SNORD114-9) and piwi-RNAs (DQ598070, DQ595173, DQ596932, DQ598479, 
DQ574699).  
 
Figure 1. Volcano plot showing the log2 fold change of the genes identified versus the log2 significance of the 
change. The red color dots represent the genes that changed significantly (p<0.05) (see Table 1). Only genes 
present in both samples are represented, so genes absent in one sample of the two samples are not shown. 
The gene that showed the most significant downregulation was SNRPD2 with a log 2 fold 
change of -3.057 and a p-value of 3.44e-14. KCTD7, HYAL3 and SETD4 followed. Only one 
small nucleolar RNAs (SNORD25) and several piwi-RNAs (DQ596074, DQ592203, 
DQ595216, DQ786325, DQ576933, DQ588370) were found to be significantly 
downregulated. 
Figure 2 shows the localization of the proteins encoded by the genes according to Uniprot 
(www.uniprot.org). SIX4, ZNF138, UFM-1, ISY1, CPEB3_ribozyme, SNRPD2, ZFP161, 
ZNF846 are positioned in the nucleus. UFM-1, CPEB3_ribozyme, SNRDP2, HYAL3, CNP, 
KCTD7 are positioned in the cytoplasm. CNTFR, C11ord10, C19orf42, LPL, IFIT5, KCTD7, 
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CNP, DQ786325 are positioned in the membrane. TIMM8A, CNP, DQ786325 (MTX1) are 
positioned in the mitochondrion. C15orf38 is positioned in the lamellipodium. SETD4 is 
proposed to be either in the nucleus or in the ribosome. There is little information about the 
positioning of FLJ45340, DQ598070, LOC100133161, AK023614, DQ596074, DM074112, 
DQ592203, FU270179, JA429802, FU270191, CHURC1-FNTB, DQ595173, C4orf43, 
AF047486, DQ595216, DQ596932, U42379, DQ598479, DQ576933, DQ574699, DQ588370 
and JA535805. 
 
Figure 2. Position of genes in the cell that are significantly (p<0.05) up or down regulated after exposure of 
human adipocytes to resistin. 
The 55 genes that are significantly differentially expressed when cells are exposed to resistin 
were uploaded to IPA software for further pathway analysis. Table 2 shows the two IPA 
networks which were shown to be important when analyzing the role of the differentially 
expressed genes, and the genes that are involved in these networks. More specifically network 
1, which included top diseases and functions such as protein trafficking, assembly and 
organization, cellular function and maintenance, scored 29 with 12 focus genes that were 
actually differentially expressed of all genes linked to this pathway. Network 2, which 
included top diseases and functions such as cell death and survival, cancer, organismal injury 
and abnormalities, scored 26 with 11 focus genes. Three additional networks identified by 
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IPA were of no importance since the score that they acquired was 1 and they are here not 
discussed further. 
Table 2. Networks identified by IPA software of differentially expressed gene profiles obtained after exposure 
of human omental adipocytes to resistin, including the score from IPA, number of focus genes (= genes obtained 
via IPA as important in our dataset), top diseases and functions of the networks and the genes involved printing 
the focus genes that were differentially expressed in bold as well as the direction of their change in expression. 
Red arrows show upregulation and green arrows show downregulation.  
Network Score Focus genes Top diseases and functions Genes 
 
 
 
 
 
1 
 
 
 
 
 
29 
 
 
 
 
 
12 
 
Protein trafficking 
↓ARPIN/C15orf38-AP3S2, 
CLPB, ↓CNP, CUL3, CUL5, 
DHX8, EGFR, HGS, HTT, 
↑IFIT5, ↑ISY1, JOSD1, KAT5, 
↓KCTD7, KRT40, ↓MTX1, 
NXF1, PPA2, ↓SETD4, 
↓SNRPD2, SOX2, SS18L1, 
STAM, STAM2, TIMM13, 
↑TIMM8A, TOMM22, 
TOMM34, TOMM40L, 
TRA2A, TSPO, XAB2, 
↓ZBTB14, ↑ZNF138, 
↓ZNF846 
 
Cellular Assembly and 
organization 
 
Cellular function and 
maintenance 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
26 
 
 
 
 
 
 
 
 
11 
 
 
Cell Death and Survival 
↑CNTFR, CYLD, DUSP6, 
E2F5, GATA6, HNF4A, 
↓HYAL3, INSR, Insulin, 
KDM2B, KLF6, Lh, ↑LPL, 
↑mir-10, ↑mir-181, ↑mir-1206, 
miR-125b-2-3p (miRNAs 
w/seed CAAGUCA), miR-
181a-5p (and other miRNAs 
w/seed ACAUUCA), MMP13, 
NLK, PTPN22, RNA 
polymerase iii, SIX2, ↑SIX4, 
Smad2/3, ↑SMIM7, STAM2, 
TIMP3,↓TMA16, ↑TMEM258, 
TP53, TRA, ↑UFM1, Vegf, 
ZEB2 
 
 
 
Cancer 
 
Organismal Injury and 
Abnormalities 
 
Discussion 
In this study we analyzed the effect of exposure to resistin on gene expression in human 
omental adipocytes. Our study shows that several genes in the adipose cells were specifically 
and significantly affected in their expression by the presence of resistin. The proteins encoded 
by these genes are localized in different cell compartments, the nucleus, the mitochondrion as 
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well as the cell membrane and cytosol.  Most genes that were differently affected by resistin 
exposure encode proteins that are localized in the nucleus.  
 Analysis of the genes and proteins encoded shows that FLJ45340 is a protein with sequence 
similarity to tousled-like kinase 2, a nuclear serine/threonine kinase suggested to be involved 
in the regulation of chromatin assembly, the cell cycle and cell differentiation, SIX4 is a 
homeobox gene, involved in transcriptional regulation, ZNF138 is a zinc-finger protein 
involved in DNA binding and linked to RNA polymerase II, UFM1 is a ubiquitin-like protein, 
involved in protein regulation, CNTFR (Ciliary neurotrophic factor receptor) has a role in 
survival, differentiation and gene expression of neuronal cells. CNTFR is proposed to be 
involved in the IL-6 pathway (Pasquin et al., 2015; Schuster et al., 2003). IL-6 is one the 
adipocytokines with increased expression in obese adipose tissue (Cabia et al., 2016). ISY1 
(ISY1 Splicing Factor Homolog) is involved in mRNA splicing. More specifically is involved 
in the first step of spliceosomal transesterification activity and in the biogenesis of pri-
miRNA which in turn is a key factor in the developmental regulation of  miRNA (Dix et al., 
1999; Villa and Guthrie, 2005; Du et al., 2015). 
 The genes which are most significantly downregulated were SNRPD2, KCTD7, HYAL3 and 
SETD4. SNRPD2 is a small nuclear ribonucleoprotein, a protein required for pre-mRNA 
splicing and small nuclear ribonucleoprotein biogenesis, KCTD7 is a potassium channel 
protein which is involved in cell membrane hyperpolarization and HYAL3 is a hyaluronidase-
like protein. Hyaluronidases are involved in degrading hyaluronan, a glycosaminoglycan 
thought to be involved in cell proliferation and differentiation. However, HYAL3 has not 
been shown to have hyaluronidase activity. The HYAL3 gene is located in a region on 
chromosome 3 with many genes associated with tumor suppression (Gerhard et al., 2004). 
SETD4 is a protein involved in ribosome biogenesis. 
In addition to the genes most significantly up or down regulated discussed above, other genes 
of interest, are also significantly upregulated, albeit to lower extent. One of these genes 
encodes lipoprotein lipase (LPL). LPL functions as triglyceride hydrolase and as 
ligand/bridging factor for lipoprotein uptake (Klop et al., 2013). LPL plays also an important 
role in the processing of triglyceride-rich lipoproteins. More specifically it hydrolyzes 
circulating chylomicrons and very low density lipoproteins (VLDL) (Jung and Choi, 2014). 
Therefore the upregulation of LPL by resistin can lead to the increased number of free fatty 
acids in the blood, which might  impair the proper storage of the fat. 
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The effects on a wide range of microRNAs shows the effect that resistin may have at the post-
trancriptional regulation of gene expression. MicroRNAs are non-coding RNAs that can alter 
the post-transcriptional regulation of gene expression by affecting the stability and translation 
of mRNAs (NCBI).  
Among the genes that are upregulated are also Piwi-interracting RNAs (piRNAs) (DQ598070 
- piRNA-36136, DQ595173 - piRNA-61285, DQ596932 - piRNA-34998, DQ598479 - 
piRNA-36545, DQ574699 - piRNA-35810) for which the function is still unclear. PiRNAs 
form complexes with piwi proteins that are related with both epigenetic and post-
transcriptional gene silencing (Seto et al., 2007). 
Also the function of C11orf10, C19orf42, MIR4731, SNORD113-1, MIR4800, SNORD114-
9, MIR611 and SNORD114-3 is still unknown and has to be further investigated. MIRs are 
microRNA’s and SNORD are small nucleoar RNA’s. The presence of these small RNA 
molecules suggests a possible regulation on mRNA stability or translation of mRNA into 
protein.  
Besides the highly significantly downregulated genes discussed above other genes that are 
downregulated are interesting to discuss. JA429802 is a gene with high similarity to 
glutamine synthetase. Glutamine synthetase is important for nitrogen metabolism in cells and 
crucial for many fundamental processes as nucleotide synthesis. CHURC1-FNTB is proposed 
to be involved in the regulation of cell proliferation. SNORD25 is also downregulated in our 
study. This gene has been referred to as a guide RNA because it functions in the biogenesis of 
other small nucleolar RNAs. ZFP161 is long non-coding RNA (lncRNA) and is a 
transcriptional activator of dopamine (DAT) transporter and transcriptional repressor of Myc 
and thymidine kinase. Decrease of DAT has been related with aging (Bannon et al.,1992). 
Myc has been identified as proto-oncogene and is involved in cell proliferation, cell growth, 
apoptosis, stem cell self-renewal and cell competition (Denis et. al., 1991; Claveria et. al. 
2013). C4orf43 is translation machinery-associated protein 16 involved in protein translation. 
For other genes downregulated, the function is still unclear. These genes are LOC100133161, 
DQ596074, DQ592203, JA429802, C4orf43, DQ595216, U42379, DQ588370, JA535805, 
FLJ27352 and AK023614.  
Overall the up- and down regulation of genes under the influence of resistin suggest 
modifications in transcriptional regulation processes with a suggested change, which is very 
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likely a decrease, in cellular differentiation and maintenance processes in the presence of 
resistin. 
Additionally, according to IPA software based pathway analysis performed  for the 55 
identified differentially expressed genes, the networks identified lead to the conclusion that 
resistin is also affecting lipid storage and usage. Altogether the results of the present study 
indicate that in the presence of resistin    adipocytes downscale cellular processes with a 
concomitant decrease in energy expenditure. These changes in energy expenditure may be a 
reflection of the survival mode in which an organism is entering to cope with bad times in 
food supply, controlling lipid metabolism and assuring cellular maintenance. In modern 
societies where the access to food is easy the need of such an ancient surviving mechanism is 
redundant and may even turn into a harmful mode of action. 
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Abstract 
Currently, there is a worldwide increase of patients with Type 2 diabetes (T2DM). T2DM is 
highly correlated with elevated serum levels of IL6, TNFα and Hp and low levels of AdipoQ 
(Badawi et al., 2010). During the progression of healthy obese to T2DM status, there is an 
influx of immune cells, in particular macrophages, into adipose tissue, accompanied by an 
increase of inflammatory cytokines. To get a better insight in the underlying mechanisms, we 
performed a quantitative mass spectrometry analysis on a modified in vitro assay, combining 
3T3L1 adipocytes and LPS activated RAW264.7 macrophages, thus mimicking inflamed 
adipose tissue. Clinically known markers, e.g. IL6, TNFα, AdipoQ, complement factor C3, B 
and D were identified, thus confirming the assay. In addition, we found 54 new proteins that 
can potentially be used for research into the mechanism of T2DM. Comparison of our results 
to a study on human visceral fat of obese non-diabetic and obese diabetic subjects, indicated 
that AUH, NAGK, pCYT2, NNMT, STK39 and CSNK2A2 have the potential of being 
prognostic biomarkers. Moreover, the expression of some of these genes was also changed in 
human blood samples at early stages of insulin desensitization. Overall, we conclude that the 
direct contact co-culture of 3T3L1 adipocytes with activated RAW264.7 macrophages is a 
mechanistically relevant and partially translational representative of inflamed visceral adipose 
tissue and can be used in identifying new “players” or biomarkers of T2DM regulation.  
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Introduction 
In many Westernized cultures there is an increase in obesity, which may develop into 
metabolic syndrome and type 2 diabetes (T2DM) (Badawi et al., 2010; Arora et al., 2011). In 
obese subjects, an increase of lipid storage by adipocytes is observed (Badawi et al., 2010). In 
addition to lipid storage, adipose tissue can also have important endocrine and 
immunoregulatory functions (Badawi et al., 2010). Notably, by producing adipokines, 
hormones and inflammatory factors, adipose tissue can influence many processes in the 
human body (Hotamisligil et al., 1995; Spiegelman et al., 1993).  
In the progression of healthy obese to a T2DM status the increase of the influx of immune 
cells, (especially macrophages) into adipose tissue is accompanied by release of inflammatory 
cytokines (TNFα and IL6 (Weisberg et al., 2003; Zhao et al., 2012)).  
Although the role of IL6, CRP and Hp in insulin resistance is not clear, there are clear 
indications on the mechanism of insulin resistance caused by the macrophage-derived 
cytokine TNFα (Hotamisligil et al., 1996). Upon activation of the TNFα receptor, the adaptor 
molecule IRS1 will become phosphorylated on a serine residue, thus inhibiting tyrosine 
phosphorylation of this adaptor molecule. Tyrosine phosphorylation of IRS1 is required for 
relaying the signal coming from the insulin receptor towards the glucose transporter GLUT4, 
which will, subsequently, translocate to the plasma membrane and allow uptake of glucose 
(Hotamisligil et al. 1996). Indeed, studies in human patients suggest that fasting serum levels 
of glucose can be lowered by using an inhibitory anti-TNFα antibody (Gupta-Ganguli et al. 
2011).  
In order to treat T2DM it is important to detect and prevent the onset of the disease as early as 
possible. However, the expression of most biomarkers which are currently used (AdipoQ, Hp, 
CRP, IL6, TNFα) only change after serum glucose levels increase above normal levels, 
suggesting that they cannot be used as early and thus truly predictive biomarkers for onset of 
disease (Arora et al., 2011). Nevertheless, these biomarkers did help to clarify that T2DM is a 
metabolism-induced inflammatory disease (Arora et al., 2011). Many studies on biomarker-
identification have been performed, both in in vitro as well as in vivo models, with varying 
results (Badawi et al., 2010; Lopez-Villar et al., 2015).  
Here, we used the co-culture system of 3T3L1 adipocytes and RAW264.7 macrophages, 
representing two cell types relevant in the onset of T2DM-related inflammation (Hotamisligil 
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et al., 1995; Spiegelman et al., 1993). We exposed the cultures to LPS, and subsequently 
analyzed protein expression by quantitative mass spectrometry analysis. We then verified the 
identified proteins in existing, published human patient data sets. This approach allowed us to 
identify new proteins/genes which may be used as early biomarkers for the development of 
T2DM in humans and help us to better understand the pathways that can lead to T2DM. 
Materials and Methods 
Cell culture and 3T3L1 differentiation 
For all cultured cells, we used DMEM F12+ Glutamax medium (Gibco 31331-028) 
supplemented with 10 % Fetal Calf Serum (Gibco 10082-147), 1% Pen/Strep (Gibco 15070-
063), and 1mM sodium pyruvate (Gibco 11360-039). 3T3L1 (ATCC ® CL-173™) and 
RAW264.7 (ATCC® TIB-71™) cells were split 1:30 every 3 to 4 days. 3T3L1 pre-
adipocytes were differentiated into adipocytes as described previously (Balvers et al., 2010). 
Briefly, cells were grown to confluency in a T75 bottle after which medium was replaced with 
fresh culture medium containing 1 μM dexamethason (Sigma D4902), 10 μg insulin/ml 
(Sigma I0516) and 0.5 mM IBMX (Sigma 1-5879). After 3 days, medium was replaced with 
culture medium supplemented with 10 μg insulin/ml. Cells were allowed to differentiate for 
an additional 5 days after which cells were reseeded in collagen-coated (Advanced Biomatrix 
5005-B) 6 well plates at a concentration of 500.000 cells per well. Cells were allowed to 
attach and grow for 2 additional days before exposure to RAW264.7 cells (50.000 cells per 
well) and E coli-derived LPS (Sigma L4391, 1 µg/ml for 18 h) were started. 
RNA isolation and real-time PCR quantification  
Briefly, RNA from each sample was isolated (Zymo Research R1055) and 200 ng of RNA 
was used for cDNA synthesis by reverse transcription (Bio Rad 170-8891). Real-time PCR 
reactions included 5 μl of diluted RT product (1:6 dilution), 10 μl FAST SYBR Green buffer 
(AB 4385614) 4,8 μl H2O and 0.5 μM forward and 0.5 μM reverse primer. Reactions were 
incubated in an Applied Biosystems 7500 Fast Real-Time PCR system in 96-well plates. The 
primers used are described in the Figure S1. Relative mRNA expression was determined by 
ddCT with HPRT mRNA expression as control. 
IL6 and TNFα ELISA 
Supernatants of exposed cells were collected and diluted 1:10 and 1:50 in ELISA dilution 
buffer according to manufacturer’s protocol (R&D cat nr DY206-05). Briefly, plates were 
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coated with capture antibody for 18 h, blocked for 1 h, washed 3x and exposed for 2 h to 100 
μl diluted supernatant from exposed cells. Then plates were washed 3x and detection antibody 
was added for another 2 h after which the plates were washed again for 3x and streptavidin-
HRP was added for 30 minutes. Plates were washed again and HRP substrate (TMB, Sigma 
T4444) was added for 10-30 minutes after which the reaction was stopped by adding 50 μl of 
1 M H2SO4. Colorimetric determination was performed in an ELISA plate reader at 450 nm 
wavelength.  
Mass spec analysis 
Four replicates of 3T3L1 adipocytes and RAW264.6 cells (untreated or LPS treated) were 
washed twice with PBS and then lysed in 250 μl of 2x concentrated Laemli sample buffer. 
Samples were sonicated for 30 min. Precast gels of 12 % of Tris-glycine sodium dodecyl 
sulfate-polyacrylamide (SDS-PAGE) (Thermoscientific) were used for the separation of the 
proteins with gel electrophoresis. In each slot 35 μl of sample-buffer (x5) diluted and boiled 
samples were added. The gel was stained with colloidal Coomasie blue (Colloidal blue 
staining kit, Thermoscientific). The gel was destained by washing twice with water. Each lane 
was cut into 5 equal pieces and placed in low protein-binding clean eppendorf tubes and were 
processed for in-gel digestion. Cysteine reduction was performed by adding 100 μl of 50 mM 
dithiotreitol (DTT) in 50 mM NH4HCO3 and incubated for 1 h at 60 
o
C by gently shaking. 
Alkylation followed by replacing DTT with 100 μl of 100 mM iodoacetamide (IAA) in 50 
mM NH4HCO3 and incubating for 1 h in room temperature by gently shaking. The enzymatic 
digestion was performed by adding 100 μl of 10ng/μl diluted in 50 mM NH4HCO3 and 
incubating overnight at room temperature. For the extraction of the proteins, samples were 
sonicated for 30 s and centrifuged shortly. Supernatants were transferred in clean low protein-
binding tubes. The pH was fixed between 2-4 by adding 10 % of TFA. The samples were 
analyzed by injecting 18 μl sample over a 0.10 * 32 mm Prontosil 300-5-C18H (Bischoff, 
Germany) pre-concentration column (prepared in-house) at a constant pressure of 270 bar 
(normally resulting in a flow of ca. 7 μl/min). Peptides were eluted from the pre-concentration 
column onto a 0.10 * 250 mm Prontosil 300-3-C18H analytical column (prepared in-house) 
with an acetonitrile gradient at a flow of 0.5 μl/min with a Proxeon EASY nanoLC. The 
gradient consisted of an increase from 9 to 34% acetonitrile in water with 1 ml/l formic acid 
in 50 minutes followed by a fast increase in the percentage acetonitrile to 80% (with 20% 
water and 1 ml/l formic acid in both the acetonitrile and the water) in 3 minutes as a column 
cleaning step. A P777 Upchurch microcross was positioned between the pre-concentration 
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and analytical column. An electrospray potential of 4.5 kV was applied directly to the eluent 
via a stainless steel needle fitted into the waste line of the microcross. Full scan positive mode 
FTMS spectra were measured between m/z 380 and 1400 on a LTQ-Orbitrap (Thermo 
electron, San Jose, CA, USA) in the Orbitrap at high resolution (60000). CID MSMS scans of 
the four most abundant multiply charged peaks in the FTMS scan were recorded in data 
dependent mode in the linear trap (MS/MS threshold = 5.000).  
LC-MS analyses 
LC-MS runs with all MS/MS spectra obtained were analyzed with MaxQuant 1.3.0.5 (Cox et 
al., 2008) using default settings for the Andromeda search engine (Cox et al., 2008; Cox et al., 
2011) except that extra variable modifications were set for de-amidation of N and Q as it was 
mentioned in a previous work (Arora et al., 2011). A mouse database downloaded from 
Uniprot (http://www.uniprot.org) was used together with a contaminants database that 
contains sequences of common contaminants as for instance: BSA (P02769, bovine serum 
albumin precursor), Trypsin (P00760, bovine), Trypsin (P00761, porcine), Keratin K22E 
(P35908, human), Keratin K1C9 (P35527, human), Keratin K2C1 (P04264, human) and 
Keratin K1CI (P35527, human). The “label-free quantification” as well as the “match 
between runs” (set to 2 minutes) options were enabled. De-amidated peptides were allowed to 
be used for protein quantification and all other quantification settings were kept default. 
Filtering and further bioinformatics analysis of the MaxQuant/Andromeda workflow output 
and the analysis of the abundances of the identified proteins were performed with the Perseus 
v.1.3.0.4 module (available at the MaxQuant suite). Accepted were peptides and proteins with 
a false discovery rate (FDR) of less than 1% and proteins with at least 2 identified peptides of 
which one should be unique and one should be unmodified. Reversed hits were deleted from 
the MaxQuant result table as well as all results showing a LFQ value of 0 for both LPS treated 
and untreated cells.  Zero values for one of the two LFQ columns were replaced by a value of 
4.5 to make sensible ratio calculations possible. Relative protein quantitation of sample to 
control was done with Perseus v1.3.0.4 by applying a two sample t-test using the normalized  
“LFQ intensity” columns obtained for LPS treated and untreated 3T3L1 adipocytes and 
RAW264.6 cells with threshold 0.05 and S0=1. 
Data analysis  
In vitro experiments were performed in triplicate and repeated at least three times in 
independent experiments. Data are presented as means with SD. Statistical analyses were 
performed on the data as depicted in the figures legends. 
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Results 
Direct contact versus indirect contact between adipocytes and macrophages 
Currently, most publications on 3T3L1 adipocytes in co-culture with RAW264.7 
macrophages describe indirect co-cultures by using transwell systems separating the 
adipocytes and the macrophages with a semi-permeable membrane that allows diffusion of 
cytokines and other cellular products, but prevents direct cellular contact (Sabater et al., 2013; 
Yamashita et al., 2007). In vivo, adipocytes and macrophages engage in direct cell-cell 
interactions and we postulate that this is important for the inflammatory response (Chatterjee 
et al. 2013). To test this, we differentiated 3T3-L1 pre-adipocytes into adipocytes for 1 week 
and subsequently reseeded the cells into collagen-coated wells and grew them for another 
week. Then, RAW 264.7 macrophages were added to the adipocytes directly (allowing cell-
cell contact) or indirectly by using a transwell or regular plates (no contact between 
macrophages and adipocytes). Cells were then co-cultured for 18 h in the absence or presence 
of LPS (1 µg/ml) to mimic an inflammatory response. We observed significantly higher levels 
of IL6 in the LPS-stimulated co-cultures with direct contact between adipocytes and 
macrophages when compared to LPS-stimulated co-cultures in which the cells were separated 
by a transwell membrane (Figure 1A). This was both observed by QPCR and ELISA, 
indicating that IL6 protein is newly synthesized. In addition, a similar effect was observed for 
IL1α mRNA expression (Figure 1B). In contrast, the LPS-induced increase in TNFα mRNA 
expression appeared to be independent of cell-cell contact or even independent of adipocytes 
(Figure 1A), suggesting that the macrophages are the main source of TNFα in this co-culture. 
In addition, AdipoQ expression decreased after LPS in both direct and indirect co-cultures to 
similar levels (Figure 1C), suggesting that this decrease is independent of cell-cell contact. 
Identification of novel proteins involved in inflamed adipose tissue 
The established co-cultures of adipocytes and macrophages were then tested for changes in 
protein expression when stimulated with LPS for 18 h. After exposure, cells were lysed and 
analyzed by LCMS (Figure 2A). From these analyses we observed 54 significantly changed 
proteins among which were Hp and complement factor B (CfB), which were both increased 
upon LPS exposure (Figure 2B). To confirm whether the increased Hp protein expression that 
we observed by mass spectrometry was due to increased gene activation, we performed 
microarray (Figure 2C) and QPCR (Figure 3A) analysis for the expression of Hp mRNA in 
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Figure 1. Direct contact between 3T3L1 adipocytes and RAW264.7 macrophages enhances inflammatory 
response. 3T3L1 adipocytes and RAW264.7 cells were either co-cultured with direct contact or separated by a 
transwell membrane. RAW264.7 cells were seeded in the upper compartment and the adipocytes in the lower 
compartment of the transwells. Cells were co-cultured and stimulated with LPS for 18 h. (A) IL6 protein and 
mRNA and TNFα mRNA were normalized to untreated adipocytes. (B) IL1α and AdipoQ mRNA were 
determined by QPCR and normalized to untreated 3T3L1 adipocytes. All experiments were performed 3 times (* 
indicates p-values which are lower than 0.01 with unpaired parametric Welch’s t-test). 
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adipocytes and macrophage co-cultures. Indeed, we observed an increase in Hp mRNA 
expression when adipocytes were stimulated with LPS, which appeared to be independent of 
macrophages (Figure 3A).  
Also complement factor B was observed to be important (Figure 2B). In humans CfB and C3 
expression levels were increased in patients with T2DM, whereas expression of adipsin was 
reported to be decreased in patients with T2DM (Wlazlo et al., 2014). The mRNA expression 
of CfB, C3, and adipsin in our study reflects observations made in vivo in other studies. In 
addition, in agreement with literature(Wlazlo et al., 2014; Barbu et al., 2015; Vlaicu et al., 
2016; van Greevenbroek et al., 2012; Moreno-Navarrete et al., 2010) and our ms data, CfB 
expression was increased when co-cultures of adipocytes and macrophages were stimulated 
with LPS for 18 h compared to non-stimulated co-cultures (Figure 3B). In contrast, C3 
mRNA was increased in LPS-stimulated monocultures of adipocytes but not in monocultures 
of macrophages (Figure 3B), suggesting that the increase of C3 mRNA observed in the co-
cultures was, most likely, produced by the adipocytes.  
When adipocytes were exposed to either macrophages or LPS, there was no significant 
decrease of adipsin observed on mRNA level. However, when adipocytes were stimulated 
with LPS in the presence of RAW264.7 macrophages, we observed a significant decrease of 
adipsin mRNA (Figure 3B). This decrease of adipsin is in line with lower levels of adipsin 
often found in human subjects suffering from T2DM (Derosa et al., 2013).  
A  
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 Protein ID Protein names Gene names ratio -Log t-test 
p value 
U
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Q3UBS3 Haptoglobin Hp 3.45 10.29 
E9Q5U3 Glyceraldehyde-3-phosphate dehydrogenase Gm10358 3.39 2.43 
B8JJN0 Complement factor B Gm20547 2.68 6.98 
P04918 Serum amyloid A-3 protein Saa3 2.67 7.49 
B7ZCQ3 Non-histone chromosomal protein HMG-17 Hmgn2 2.57 1.61 
Q6ZQH8 Nucleoporin NUP188 homolog Nup188 2.39 1.61 
Q8C845 EF-hand domain-containing protein D2 Efhd2 2.14 8.48 
B2RTB0 28 kDa heat- and acid-stable phosphoprotein Pdap1 2.02 1.99 
Q9Z1G4 V-type proton ATPase 116 kDa subunit a isoform 1 Atp6v0a1 2.00 1.72 
Q66JR8 Ptms protein Ptms 1.98 1.50 
A0JNY3 Gephyrin Gphn 1.96 1.59 
P15116 Cadherin-2 Cdh2 1.86 6.54 
B1B079 Zinc finger CCCH domain-containing protein 15 Zc3h15 1.86 2.16 
P17095 High mobility group protein HMG-I/HMG-Y Hmga1 1.75 1.61 
Q3UGJ5 Ras GTPase-activating protein 3 Rasa3 1.67 7.15 
P99027 60S acidic ribosomal protein P2 Rplp2 1.66 4.97 
P54987 Immune-responsive gene 1 protein Irg1 1.64 5.27 
P29533 Vascular cell adhesion protein 1 Vcam1 1.41 6.64 
Q6IRU2 Tropomyosin alpha-4 chain Tpm4 1.39 5.08 
D
o
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r
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u
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Q541Z2 Protein farnesyltransferase/geranylgeranyltransferase  Fnta -1.18 4.62 
A2AVJ6 COMM domain-containing protein 9 Commd9 -1.28 5.96 
D3Z312 Tumor necrosis factor alpha-induced protein 8 Tnfaip8 -1.46 4.61 
O54833 Casein kinase II subunit alpha Csnk2a2 -1.49 4.64 
Q9D967 Magnesium-dependent phosphatase 1 Mdp1 -1.51 2.32 
Q8R3Q6 Coiled-coil domain-containing protein 58 Ccdc58 -1.52 2.09 
A2AQL0 STE20/SPS1-related proline-alanine-rich protein kinase Stk39 -1.53 6.70 
Q3TWT5 Acid ceramidase Asah1 -1.58 1.77 
Q6P069 Sorcin Sri -1.64 1.77 
P67871 Casein kinase II subunit beta Csnk2b -1.66 1.61 
P40336 Vacuolar protein sorting-associated protein 26A Vps26a -1.67 1.62 
Q3UBR8 Mitochondrial import inner membrane translocase Timm17b -1.71 1.70 
Q8VE96 Transmembrane protein C2orf18 homolog 4930471M23Rik -1.79 7.40 
Q9JKV1 Proteasomal ubiquitin receptor ADRM1 Adrm1 -1.81 1.60 
Q924D0 Reticulon-4-interacting protein 1, mitochondrial Rtn4ip1 -1.82 1.49 
P50428 Arylsulfatase A Arsa -1.84 2.19 
A2AN96 Putative hydrolase RBBP9 Rbbp9 -1.85 2.10 
Q3TA37 Elongation factor Ts Tsfm -1.89 7.87 
Q01149 Collagen alpha-2(I) chain Col1a2 -1.90 5.93 
B1B0W8 Hypoxanthine-guanine phosphoribosyltransferase Hprt -1.90 1.53 
E9Q272 Protein Hook homolog 3 Hook3 -1.92 7.71 
O55239 Nicotinamide N-methyltransferase Nnmt -1.92 5.78 
Q7TNL5 Serine/threonine-protein phosphatase 2A 56 kDa regulatory Ppp2r5d -1.95 1.94 
Q542Y0 NAD(P)H dehydrogenase [quinone] 1 Nqo1 -1.96 1.48 
P20918 Plasminogen Plg -2.13 2.16 
Q3USD5 Ethanolamine-phosphate cytidylyltransferase Pcyt2 -2.19 7.48 
Q99LY9 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 Ndufs5 -2.19 7.11 
Q9D997 N-acetyl-D-glucosamine kinase Nagk -2.20 7.79 
Q8C0E2 Vacuolar protein sorting-associated protein 26B Vps26b -2.20 9.81 
Q9JLZ3 Methylglutaconyl-CoA hydratase, mitochondrial Auh -2.25 5.76 
Q3UWG5 CD81 antigen Cd81 -2.34 3.04 
A2AMS1 Sigma non-opioid intracellular receptor 1 Sigmar1 -2.43 6.15 
P61082 NEDD8-conjugating enzyme Ubc12 Ube2m -2.45 9.38 
A3E4B1 ATP synthase protein 8 ATP8 -2.46 1.55 
O70456 14-3-3 protein sigma Sfn -2.60 1.57 
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Figure 2. Quantitative mass spectrometry and mRNA analysis of LPS-stimulated co-cultures of 3T3L1 
adipocytes and RAW264.7 macrophages. 3T3L1 adipocytes and RAW264.7 cells were co-cultured and 
stimulated with LPS (1 µg/ml) for 18 h. (A) Vulcano plot of identified proteins in quantitative mass 
spectrometry, showing proteins that become upregulated upon LPS treatment on the positive right side and 
downregulated proteins on the negative left hand side in the figure. T-test p-values are shown on the y-axis as “–
Log p-value”. (B) Table showing proteins (with their gene names) that have changed their expression after LPS 
stimulation as determined by quantitative mass spectrometry. Proteins that change their mRNA expression in 
humans are indicated in Bold. (C) mRNA expression, of proteins identified in quantitative mass spectrometry, in 
adipocytes versus co-cultures of adipocytes and RAW264.7 macrophages which were stimulated with LPS (1 
µg/ml) for 18 h. All experiments were performed 3 times (* indicates p-values which are lower than 0.01 with 
unpaired parametric Welch’s t-test). 
These observations suggest that a macrophage-derived factor might be responsible for the 
reduced expression of adipsin, possibly TNFα and/or IL6. Therefore, we tested whether IL6 
or TNFα themselves can alter the expression of CfB, adipsin and C3 to the same level as 
observed with LPS stimulation in co-cultures of 3T3L1 and RAW264.7 cells. Indeed, when 
TNFα was added to 3T3L1 adipocytes, there was an increase of CfB and C3, and a decrease 
of adipsin to similar levels as observed for LPS-stimulated co-cultures, whereas IL6 did not 
affect the expression of these complement factors (Figure 3C). This suggests that TNFα is a 
key player in the regulation of complement expression by adipocytes. 
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Fig 3 TNFα is a key-player in complement expression by 3T3L1 adipocytes and RAW264.7 macrophages. 
3T3L1 adipocytes and RAW264.7 cells were co-cultured and stimulated with LPS (1 µg/ml) or TNFα (1 ng/ml) 
for 18 h where indicated. (A) Hp mRNA was determined by QPCR and normalized to untreated adipocytes. (B-
C) CfB, adipsin and C3 mRNA were determined by QPCR and normalized to untreated 3T3L1 adipocytes. All 
experiments were performed 3 times (* indicates p-values which are lower than 0.01 with unpaired parametric 
Welch’s t-test). 
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Visceral adipose tissue in healthy obese versus T2DM obese women  
To further identify whether the protein hits from our mass spec analysis are relevant as 
biomarkers for human studies, we analyzed a publicly available human gene expression data 
set of visceral adipose tissue of 10 Indian obese women (Mathur et al. 2013). Five of these 
subjects were healthy obese and five were indicated as having T2DM. Both groups were 
matched for BMI. Expression of the 54 genes of the proteins we identified in our mass spec 
analysis as important with a notable difference between healthy obese and T2DM obese 
subjects are shown in Figure 4.  
A decreased expression for VPS26A, VPS26B, pCYT2, AUH, STK39 and CSNK2A2 and an 
increase for VCAM1, EFHD2 and SAA1 (human orthologue for mouse SAA3), are in 
agreement with our mass spec data (Figure 4, Figure 2). However, NAGK and NNMT mRNA 
showed an increase in expression in vivo, whereas, we observed a decreased expression in 
vitro on protein level. Of note, not all of the 54 newly identified proteins, whose expression 
changed in our in vitro T2DM inflammatory model, showed an altered gene expression in the 
T2DM obese subjects compared to healthy obese subjects in the in vivo study on obese Indian 
women  (Mathur et al. 2013). This could be due to differences between human versus mouse, 
in vivo versus in vitro or simply protein versus mRNA expression. To test the latter, we 
compared mRNA array data and proteomics data from 3T3L1 adipocytes and LPS-stimulated 
co-cultures of 3T3L1 adipocytes and RAW264.7 macrophages (Figure 2). For most of the 
genes that showed a difference in mRNA expression in diabetic versus non-diabetic obese 
women, we also observed a difference in mRNA expression in our in vitro model, suggesting 
that differences found between our in vitro proteomics data and the in vivo mRNA data from 
Mathur et al. (2013) is mainly because of differences between mRNA versus protein 
expression. 
Currently, visceral fat is considered to have a larger impact on the development of T2DM 
than subcutaneous fat (Wajchenberg et al., 2002). To test whether the observed differences in 
gene expression were specific for visceral fat or can also be observed in subcutaneous fat 
from subjects suffering from T2DM, we analyzed the expression of the genes from figure 2A 
as compared to a published study on human subcutaneous adipose tissue data sets from 
healthy and T2DM donors (Keller et al., 2011). Whereas we observed changes in gene 
expression levels upon T2DM development in visceral fat, no differences in gene expression 
were observed in subcutaneous fat from healthy obese versus T2DMobese patients (Figure 
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S2). This accounted for all 54 newly identified genes (Figure S2) and AdipoQ (Figure S2), 
suggesting that the in vitro co-culture reflects visceral adipose tissue rather than subcutaneous 
adipose tissue (Figure S2). 
Some significant visceral adipose markers are reflected in blood  
When using biomarkers as indicators for disease progression, blood samples are more easily 
obtained than visceral adipose tissue samples. The proteins, observed in our study, can be 
either produced by adipocytes, macrophages or both. Although adipocytes, most likely, will 
not easily enter the blood or lymphatic system, the more motile macrophages can. So 
therefore, we analyzed in another publicly available dataset (Karolina et al., 2011) whether 
the expression of the genes from Figure 2 is significantly changed in blood samples from 
obese male adult human subjects with either a normal fasting glucose level, an impaired 
fasting glucose (IFG) level or diagnosed as T2DM patient. As a control, we first checked 
whether the expression of currently used biomarkers, such as AdipoQ and Hp (Badawi et al., 
2010; Quaye et al., 2008; Chiellini et al., 2004; Lisi et al,. 2011; Maffei et al., 2016), were 
changed in the blood cell analyses of that study. Indeed, expression of AdipoQ and Hp 
decreased and increased, respectively, in subjects with decreased insulin sensitivity or T2DM 
(Figure 5). Although not all genes in blood changed their expression as compared to our 
analysis on visceral fat, we noted a downregulation of pCYT2 (expressed highly by 
RAW264.7), STK39, NAGK and SAA1 and a slight up-regulation of NNMT and AUH 
mRNA in blood of subjects with IFG and T2DM (Figure 5). This suggests that products of 
these genes can potentially be used as prognostic markers for insulin sensitivity.  
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Figure 4. mRNA expression in obese non-diabetic and obese diabetic Indian women of genes identified in 
quantitative mass spectrometry. Through literature data mining we determined the mRNA expression of genes 
identified through proteomics in 5 obese non-diabetic and 5 obese diabetic women. Every data point represents 1 
subject (* indicates p-values which are lower than 0.05 with non-parametric t-test according to Mann-Whitney). 
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Figure 5. mRNA expression in blood samples of healthy obese, IFG and T2DM subjects of genes identified in 
quantitative mass spectrometry. Through literature data mining we determined the mRNA expression, of genes 
identified through proteomics, in blood samples which were obtained from obese male adult human subjects (21 
to 70 years of age) with normal fasting glucose (<6.1 mmol glucose/L), impaired fasting glucose (IFG) (6.0 
mmol glucose/l - 7.0 mmol glucose/L) and T2DM (>7.0 mmol glucose/L) (Karolina et al., 2011). Every data 
point represents 1 subject (* indicates p-values which are lower than 0.05 with non-parametric t-test according to 
Mann-Whitney). 
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Druggable targets in co-culture of adipocytes and macrophages. 
To test whether our in vitro model can be used for drug screening we tested rosiglitazone. 
Rosiglitazone is known for its beneficial effect on insulin sensitivity in humans by activating 
PPARγ and increasing AdipoQ (Starner et al., 2008). To test whether rosiglitazone can affect 
the expression of IL6, TNFα, Hp, AdipoQ or adipsin in the in vitro co-cultures, we exposed 
3T3L1 adipocytes, RAW264.7 and 3T3L1/RAW264.7 co-cultures to rosiglitazone during 
LPS stimulation analyzing the expression of IL6, TNFα, Hp, AdipoQ or adipsin.  After an 
overnight exposure, ELISAs for IL6 and TNFα (Figure 6A) indicated that rosiglitazone 
inhibited LPS-induced IL6 and TNFα secretion, which points to a beneficial effect for insulin 
sensitivity. 
The rosiglitazone-samples were tested for mRNA expression of Hp, AdipoQ and adipsin by 
QPCR (Figure 6B) and noticed that, similar to what is observed in humans, rosiglitazone can 
increase AdipoQ mRNA expression in adipocyte mono-cultures (Figure 6B).  However, this 
beneficial effect of rosiglitazone on AdipoQ is completely abolished when adipocytes were 
co-cultured with macrophages in the presence of LPS. In addition, rosiglitazone caused a 
higher Hp mRNA expression but could not prevent the LPS-induced decrease of adipsin 
(Figure 6B). This suggests that rosiglitazone can affect T2DM through multiple pathways. 
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Fig 6 Involvement of PPARγ agonist in adipocyte inflammation. 3T3L1 adipocytes and RAW264.7 cells were 
co-cultured and stimulated with LPS (1 µg/ml) for 18 h where indicated. (A) IL6 and TNFα protein 
concentrations were determined by ELISA and normalized to untreated adipocytes. (B) Hp, AdipoQ and adipsin 
mRNA expression was determined by QPCR normalized to untreated adipocytes (* indicates p-values which are 
lower than 0.01 with unpaired parametric Welch’s t-test). 
Discussion 
Through mass spec analysis on an in vitro co-culture of macrophages and adipocytes we have 
shown that this model might be helpful in researching many aspects of T2DM development as 
indicated by the altered expression of known biomarkers, such as AdipoQ, Hp, TNFα and IL6 
(Badawi et al., 2010; Hotamisligil et al., 1996; Maffei et al., 2016; Xita and Tsatsoulis, 2012). 
Importantly, most of the known biomarkers for T2DM are produced by visceral adipose tissue 
rather than by subcutaneous adipose tissue (Badawi et al., 2010; Wajchenberg et al., 2002) 
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(Figure S2). Both protein and mRNA expression profiles of these known biomarkers, confirm 
that our in vitro co-culture system has more overlap with visceral adipose tissue then 
subcutaneous adipose tissue. Also newly identified proteins (a.o. pCYT2, NNMT, STK39, 
NAGK, SAA1, VPS26A&B and AUH) in our study were confirmed by comparison to a 
published study on human mRNA expression. These proteins have the potency to be used as 
biomarkers for T2DM progression. The observed biomarkers can be linked to pathways for a 
better understanding of the development of T2DM and to design specific therapeutic 
approaches (Figure 7). Here, we will discuss the potential roles of the proteins in T2DM we 
observed to change their expression in vitro and in vivo (Figure 7). First we will discuss key 
regulator TNFα followed by other biomarkers from this study that are promising but with a 
hitherto less well known role in T2DM development. 
TNFα  
A key molecule in insulin desensitization is TNFα, well known to inhibit insulin receptor 
signaling pathways by blocking IRS1 function, and subsequently GLUT4-mediated glucose 
transport across the plasma membrane (Hotamisligil et al., 1995). Although TNFα is an 
important factor in insulin resistance it is still not clear whether other pathways emanating 
from the TLR4 receptor might also play an important role in T2DM. Hence, in the co-cultures 
of adipocytes and macrophages we induced TNFα expression through activation of TLR4 by 
LPS. Besides its effect on IRS1 functioning, it is also possible that TNFα has other ways of 
affecting diabetes. Indeed, in our studies we show that TNFα regulates the expression of CfB, 
C3, and adipsin in 3T3L1 adipocytes (Figure 3). Adipsin from adipocytes, which is 
downregulated by TNFα, is involved in the production of C3a from C3, the first being a 
recently newly identified secretagogue for insulin (Lo et al., 2014). Although we observed an 
increase of C3 mRNA, we found a decrease in adipsin mRNA, suggesting that less C3a will 
be produced after TNFα exposure. This indicates that TNFα might not only be involved in 
desensitizing the insulin receptor but also in regulating insulin secretion by the pancreas. 
Although TNFα can induce the expression of most biomarkers, it is striking that the 
expression of TNFα is lower in the LPS-stimulated co-cultures of 3T3L1 and RAW246.7 then 
in RAW264.7 mono-cultures, whereas the induced expression and secretion of IL6 and IL1α 
is much higher in the direct contact co-cultures. This suggests that TNFα is not the only 
protein involved in the inflammatory response of these co-cultures. 
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pCYT2 
One of the down-regulated proteins upon LPS stimulation of adipocyte/macrophage co-
cultures was pCYT2, an enzyme involved in de novo biosynthesis of PE 
(phosphatidylethanolamine) from ethanolamine and diacylglycerol. (Pavlovic et al., 2013). 
pCYT2
+/-
 mice, containing less of this enzyme, show elevated lipogenesis and lipoprotein 
secretion, hypertriglyceridemia, obesity, and insulin resistance (Fullerton et al., 2009). This 
suggests that decreased expression of pCYT2 as a result of inflamed adipose tissue, could be 
one of the underlying mechanisms involved in T2DM development. 
NNMT 
Another protein whose expression decreased after LPS treatment in vitro was NNMT (Figure 
2).The mRNA expression of NNMT, on the other hand, was increased in obese non-diabetic 
vs. obese diabetic Indian women (Figure 4). Recently, the importance of NNMT for T2DM-
related health effects was demonstrated by showing that NNMT expression was markedly 
increased in adipose tissue of GLUT4
-/-
 mice (Kraus et al., 2014). Moreover, NNMT 
knockout (NNMT
-/-
) mice were protected against diet-induced obesity and showed improved 
glucose tolerance while inhibition of NNMT increased adipose NAD+ levels which is related 
to  energy metabolism (Kraus et al., 2014). The finding in the human study with Indian 
women is in agreement with the data observed in NNMT
-/-
 mice. The discrepancy of these in 
vivo findings with the observed decreased NNMT expression in our in vitro model cannot be 
explained by a difference between mRNA and protein, because the NNMT mRNA expression 
in our LPS-stimulated in vitro co-cultures did not change compared to non-stimulated co-
cultures (Figure 2). Perhaps, the decreased expression found in vitro is a result of a short-term 
TLR4 stimulation, as cells may behave differently when cells are exposed to TLR4 agonists, 
such as LPS or Fetuin/Free Fatty Acids complex (Pal et al., 2012), for a longer period, e.g. 
weeks or months, which might be the case in vivo. 
STK39 
A third protein we found down-regulated after treating adipocyte/macrophage co-cultures 
with LPS was STK39/SPAK (Figure 2 and 4). The serine/threonine kinase STK39/SPAK is 
part of the WNK (With-No-Lysine)/SPAK/NCC pathway that regulates sodium and 
potassium transport across the plasma membrane (Moriguchi et al., 2005; Gagnon and 
Delpire, 2010). Besides changes in expression of STK39/SPAK, it has been observed that 
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STK39/SPAK and its substrate NCC (Na-Cl co-transporter), are highly phosphorylated in 
hyperinsulinemic db/db mice compared to non-diabetic db/db mice (Nishida et al., 2012), 
indicating a role for STK39 and NCC in the development of T2DM. In addition, clinical 
studies with the NCC specific inhibitor, thiazide, used to prevent high blood pressure, showed 
that patients with diabetes increase their fasting glucose and decrease their insulin sensitivity 
after administration of thiazide, indeed suggesting that the WNK/SPAK/NCC-pathway is 
involved in increasing insulin resistance (Eriksson et al., 2008; Hirst et al., 2015). Besides 
affecting NCC, STK39/SPAK can also inactivate the chloride-transporter CFTR, which is 
involved in Cystic Fibrosis (Yang et al., 2011). This raises the question whether this 
transporter might be involved in diabetes. Recently, a new CFTR-activating drug (Ivacaftor) 
was developed, which is currently used as a treatment for a sub-population of CF patients and 
preliminary data with Ivacaftor show that CF patients suffering from the first stage of diabetes 
revert their fasting glucose levels to normal when treated with this drug (Bellin et al. 2013). 
This indeed suggests that the WNK/STK39/NCC pathway might be involved in T2DM 
development and can be a potential druggable target (Bellin et al. 2013).  
NAGK 
NAGK was found to be upregulated after LPS treatment in vitro and in vivo (Figure 2 and 4) 
but has never been functionally linked directly to T2DM. NAGK is a kinase that 
phosphorylates N-acetyl-glucosamine (GlcNac) (Berger et al., 2002; Weihofen et al., 2006) 
and it has been described that increased O-linked beta-N-acetylglucosamine (O-GlcNAc) is 
associated with insulin resistance in muscle and adipocytes (Copeland et al., 2008; Myslicki 
et al., 2014). In addition, GlcNac might be involved in insulin receptor signaling by regulating 
the interaction between PI3K and the Insulin Receptor Substrates 1 and 2 (IRS1 and 
IRS2)(Klein et al., 2009; Whelan et al., 2010), suggesting that GlcNac and perhaps its kinase 
NAGK play an important role in insulin signaling.  
SAA 
The human acute-phase serum amyloid A protein 1 (hSAA1) is produced in adipose tissue 
(Sjoholm et al., 2005) and, in agreement with our data, the expression of this inflammatory 
adipokine correlates with metabolic complications, such as atherosclerosis and insulin 
resistance (Yang et al., 2006). In our study, we used LPS-mediated activation of TLR4 as a 
trigger for insulin resistance, however, in vivo the expression of mSAA3 (homologue of 
hSAA1) can also be triggered by a high fed-diet (HFD) and the expression of mSAA3 
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correlates with the onset of insulin resistance (Scheja et al., 2008). Moreover, exposure of 
3T3L1 adipocytes to SAA3, caused alterations in gene expression, which closely resembled 
those observed in HFD-mice (Scheja et al., 2008).   
VPS26B 
VPS26B is another protein that was down-regulated in our co-culture system after LPS 
exposure. VPS26A and B are part of the prototypical heteropentameric mammalian retromer 
(sorting nexin (SNX)-BAR retromer) complex that regulates the translocation of GLUT4 from 
endosomes to the Trans-Golgi-Network (TGN) (Ma et al., 2014). When expression of VPS26 
is lost, GLUT4 is no longer transported to the TGN but rather redirected to lysosomes, where 
it will be degraded (Ma et al., 2014). This redirection is dependent on CSNK2-activity and 
inhibition of CSNK2 blocks the lysosomal targeting and degradation of GLUT4 (Ma et al., 
2014). In our study, both VPS26 and CSNK2 are down regulated in protein and mRNA 
expression in vitro (Figure 2) and in vivo (Figure 4), suggesting that VPS26 and CSNK2 are 
important factors in reduction of glucose transport.  
AUH 
Finally, the protein expression of AUH, an RNA-binding protein with enoyl-CoA hydratase 
activity (Nakagawa et al., 1995), decreases upon LPS stimulation in co-cultures of adipocytes 
and macrophages. However, the mRNA expression of this gene is upregulated in blood 
samples of subjects that have increased glucose levels (Figure 5). Currently, there are no 
papers describing a role for this protein in diabetes, however, this crotonase can hydrate the 
double bond between the second and third carbons in acyl-CoA (Nakagawa et al., 1995), 
suggesting that it might be involved in lipogenesis and thus has the potency of linking AU-
specific RNA elements to metabolism. 
3T3L1 adipocytes have been used in many studies for unraveling the pathways of 
adipogenesis, insulin signaling and T2DM development. Most of these studies focus on 
known targets or try to identify new genes, based on mRNA expression profiles by 
microarray-based techniques (Vikman et al., 2014; Dehwah et al., 2012; Mori et al., 2012), 
whereas only a few papers have been published with respect to proteomics on adipose tissue 
(Lopez-Villar et al., 2015; Fang et al., 2015). In this paper, we show that many relevant genes 
change their protein expression without significantly changing their mRNA levels (Figure 2).  
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The co-cultures of adipocytes and macrophages have expression profiles that are more 
comparable to visceral then subcutaneous adipose tissues (Figure 4, S2) and, as such, are very 
interesting as an in vitro model for drug screening (Figure 6) and research on signaling 
pathways involved in insulin sensitivity (Figure 1, 2 and 7). In addition, we identified genes 
that are known factors in development of atherosclerosis indicating that this in vitro model 
might also help to clarify the role of inflamed adipose tissue in other aspects of the metabolic 
syndrome and might not be restricted to diabetes.  
 
Figure 7. Schematic overview of identified proteins. Inflamed adipose tissue is in this model represented by co-
culture of adipocytes and macrophages, stimulated with LPS. Red arrows indicate the change in expression after 
LPS-exposure. Green arrows indicate the change in expression when the WNK/STK39/SPAK/NCC is activated. 
Blue arrows indicate downstream pathways. 
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Supplementary figures 
 
Figure S1. QPCR primers. 
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Figure S2. mRNA expression in visceral and subcutaneous sample of obese non-diabetic and obese diabetic 
subjects. We analyzed the mRNA expression, of genes identified through proteomics, in visceral and 
subcutaneous adipose tissue of healthy obese versus T2DM obese from published data sets. Every data point 
represents 1 subject. * indicates p-values which are lower than 0.05 with non-parametric t-test according to 
Mann-Whitney.
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Discussion 
One of the most frequent diseases related to lifestyle and obesity is type 2 diabetes mellitus 
(T2DM). Diabetes results when the body is unable to produce sufficient amounts of insulin or 
does not respond properly to insulin. Insulin is the hormone that regulates the level of glucose 
in blood (Saltiel et al., 2001). The increase of glucose in the blood in T2DM may cause 
hyperglycemia that leads to long term complications.  
T2DM is the most common type of diabetes and is a result of impaired activity of β-cells, 
which are the cells that produce insulin, in combination with the reduced insulin sensitivity of 
the insulin-targeted organs. T2DM is closely related with the metabolic syndrome which is 
described by abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, insulin 
resistance and prothrombotic and proinflammatory states (Tenenbaum et al., 2003). Obesity is 
also characterized by “low grade” chronic inflammation (Monterio et al., 2010), or as 
metabolically triggered inflammation (metaflammation) (Hotamisligil, 2006) or 
parainflammation, meaning the state between normal and inflammation states (Medzhitov, 
2008). Until now, the treatments for diabetes did not have a preventive character for the 
complications associated with diabetes, such as neuropathy, retinopathy and nephropathy 
(Segev et al., 2003). Usually treatments focused on the use of exogenous insulin to control the 
level of glucose or on the transplantation of the whole-pancreas organ which has been the 
most effective treatment for diabetic people with severe complications, until now (Bonner-
Weir et al., 2005). One of the major drawbacks of this approach is the limited supply of donor 
tissues (Weir et al., 1997). Until recently one of the focus points for medication for T2DM 
was on the use of peroxisome proliferator-activated receptor gamma (PPARγ) agonists. 
Specific ligands for PPARγ are thiazolidinediones (TZDs) (Berger et al., 2002; Yki-Jarvinen, 
2004). However, only pioglitazone has remained in use after troglitazone and rosiglitazone 
were withdrawn from the market because of hepatotoxicity and increased risk of heart attacks, 
respectively. In some countries however even pioglitazone has been withdrawn because of its 
possible association with increased incidence of bladder tumors. Recently new strategies, such 
as the GLP-1 agonists and DPP-4 inhibitors started being established as potential T2DM 
therapies and they start to be recognized by the American and European Diabetes 
Associations (Nauck 2016). 
T2DM is a systemic disease which makes it difficult to identify and establish proper targets 
for the treatment or cure of the patients. Until recently research was focused on the main 
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target organs such as the pancreas and the skeletal muscle. Nowadays, after the adipose tissue 
has been characterized as an organ, research focuses on adipocytes and their role in the 
disease (Galic et al., 2010).  
The aim of this project was to define novel targets for the possible development of drugs for 
T2DM. Optimization of present preventive therapies including development of less expensive 
drugs may be of help. In the present thesisa search for novel biomarkers and drug targets for 
T2DM was undertaken. 
Chapter 1 of the thesis provided an introduction to the topic and an overview of T2DM and 
the mechanisms behind it. T2DM results from impaired insulin production by the beta-cells of 
the pancreas and from the inability of the peripheral organs targeted by insulin to exert 
adequate glucose uptake from the blood leading to insulin resistance. In this thesis we focused 
especially on possible new drug strategies and novel drug targets that deal with insulin 
resistance. 
In chapter 2 we focused on another possible target for insulin therapy in addition to PPAR 
and investigated whether resistin downregulation in mouse adipocytes would provide an 
alternative for PPARγ agonist activity when testing new diabetic drugs. The results obtained 
revealed significant correlations between the EC50 for PPARγ activation in a reporter gene 
cell line and resistin downregulation in mouse adipocytes, and between the IC50 for resistin 
downregulation and the minimum effective dose for antihyperglycemic activity in a mouse 
model. These correlations indicate that PPAR mediated downregulation of resistin might 
promote insulin sensitivity and that downregulation of resistin in mouse adipocytes provides 
an adequate bioassay for screening of newly developed antihyperglycemic compounds. These 
findings can assist in the finding of insulin sensitizing compounds by using resistin as a target. 
Resistin is a hormone that is involved in inflammation and insulin resistance (Saltiel et al., 
2001; Steppan et al., 2005; Lazar et al., 2007; Owecki et al., 2011). Resistin mRNA is mainly 
found in adipose tissue in mouse and in adipose tissue and macrophages in human. On the 
other hand resistin is found in blood which means that resistin can be distributed over and 
affect the whole body. The most important is that resistin is a link of obesity to T2DM since 
elevated levels of resistin were found in diabetes patients (Hartman et al., 2002; Lazar, 2007; 
Rajala et al., 2004; Stofkova et al., 2010). Exactly this link makes resistin an interesting 
possible novel target in this field of studies. Interesting is the fact that until now the actual 
receptor of resistin is not known. Few speculations by different research groups suggested 
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different receptors but this has to be further confirmed. One of the proposals is the 
involvement of  the Toll-like receptor 4 (TLR-4) and this was investigated in more detail in 
Chapter 3 since it would provide an interesting novel target for development of new drugs for 
2TDM. 
In chapter 3, we investigated if a known commercially available assay for TLR-4 binding can 
be used for detecting compounds that could assist in defining novel drugs for insulin 
sensitivity (Tarkowski et al., 2010). TLR-4 is a receptor known to be involved in 
inflammation and to be correlated with insulin sensitivity (Tarkowski et al., 2010). In Chapter 
3 we investigated whether a reporter assay detecting TRL-4 mediated gene expression could 
be a possible bioassay to detect candidate drugs able to inhibit resistin mediated TLR-4 
activation and subsequent effects. If so, inhibition of this resistin mediated activity may prove 
a novel target for development of new generations of antidiabetic drugs. To detect activation 
of TLR-4 mediated gene expression and enable detection of possible antagonists for resistin 
mediated activation of the receptor, a TLR-4 reporter gene cell line (HEK-Blue-TLR-4) was 
applied. The results obtained in chapter 3 reveal that resistin, like the natural TLR-4 ligand 
lipopolysaccharide (LPS) is able to activate TLR-4 mediated gene expression with EC50 
values for LPS and resistin amounting to respectively 0.05 μg/ml and 5 μg/ml.  Resistin was 
also shown to compete with LPS for binding to TLR-4 in a human epithelial cell line and to 
promote overall inflammation (Tarkowski et al., 2010; Benomar et al., 2012).  The LPS or 
resistin dependent induction of TLR-4 mediated gene expression was inhibited by two known 
TLR-4 inhibitors including LPS-RS (Visintin et al., 2005) and Polymyxin B (Duff et al., 
1982). It is concluded that the TLR-4 reporter gene cell line provides a novel tool to detect 
resistin antagonists and may be of use as a new target to screen for a possible new type of 
antidiabetic drugs. 
The importance of resistin in insulin sensitivity and T2DM has been established by several 
researchers. In chapters 2 and 3 of the thesis we investigated methods that include resistin and 
would help the identification of compounds interfering with the possible role of resistin in 
impairment of insulin sensitivity. To further increase the possible identification of novel 
targets for antidiabetic drugs via the possible role of resistin we focused in chapter 4 on the 
mechanism behind resistin mediated effects by exposing adipocytes to resistin and analyzing 
the effects on genes expression. Thus we identified genes in adipocytes that were up or down 
regulated upon their exposure to resistin. Overall the results showed that resistin upregulates 
or downregulates a large set of genes in the adipocytes. The protein products of the genes up- 
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or downregulated are located mostly in the nucleus but also in the cell membrane, in the 
cytoplasm and in the mitochondria. It was also observed that several miRNAs were 
influenced in the presence of resistin.  From the gene expression data it can be observed that 
resistin is involved in the downscaling of cellular maintenance and cellular processes. Resistin 
is in addition involved in lipid storage. From these observations we propose that resistin is 
expressed when energy conservation is essential. When energy conservation is accompanied 
by food overconsumption, obesity, inflammation and insulin resistance can be the 
consequence. Resistin can therefore be considered as a biomarker protein for these health 
related issues. 
In chapter 5 we continued the search for novel targets for T2DM drugs using an in vitro 
model that mimics inflamed adipocytes by combining 3T3-L1 adipocytes and activated 
RAW264.7 macrophages, producing an environment for testing compounds under conditions 
more similar to the in vivo situation in T2DM patients.  Using this cell model we identified 
new proteins and we confirmed these proteins by literature data-mining on human mRNA 
expression of visceral fat of obese healthy versus obese T2DM subjects. These proteins have 
the potency to be used as biomarkers for T2DM progression. Furthermore, the observed 
biomarkers are connected to pathways that will assist to describe the development of T2DM 
and consequently to design more specific therapeutic approaches. Importantly, our results also 
indicate that the in vitro approaches we have undertaken are translational to the human 
situation.  
The co-cultures of adipocytes and macrophages have expression profiles that are comparable 
to visceral adipose tissues and, as such, are very interesting as an in vitro model for drug 
screening and research on signaling pathways involved in insulin sensitivity. In addition, we 
identified proteins that are known factors in the development of atherosclerosis (Kraus et al., 
2014; Yang et al., 2006), indicating that this in vitro model can also help to clarify the role of 
inflamed adipose tissue in multiple other aspects of the metabolic syndrome and it is not 
restricted to diabetes. 
Al together it is concluded that the contact co-culture of 3T3-L1 with activated RAW264.7 is 
a mechanistically relevant and translational representative of inflamed visceral adipose tissue, 
which links to development of T2DM and can be used in identifying biomarkers of T2DM 
regulation. 
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Future perspectives 
As mentioned above T2DM results in insufficient insulin production and impaired insulin 
uptake by the targeted peripheral organs (insulin resistance). In this thesis we focused mainly 
on searching for novel targets that can be of use in defining new strategies and methods to 
overcome insulin resistance. Based on the results presented here and on other scientific 
literature additional strategies can be formulated, focusing not only on insulin resistance but 
also on insulin production. Some future perspectives, directions and suggestions that follow 
from this work and the results obtained in the present thesis are discussed in the following 
sections.  
Future perspective: Stem cell based models 
In the present thesis adipocytes as well as inflamed adipocytes consisting of cocultures of 
3T3-L1adipocytes and RAW264.7 macrophages were used to define novel models for 
defining drugs for T2DM. Novel stem cell based approaches will provide even more 
challenging and promising approaches for the future. Human embryonic stem cells are 
pluripotent and self-renewing cells derived from the inner cell mass of a fertilized egg, which 
has been cultured in vitro to reach the blastocyst stage (5-7 days after fertilization) (Thomson 
et al., 1998). Their inherent abilities (i) to indefinitely proliferate in the undifferentiated form, 
(ii) to differentiate in all three germ layers, under appropriate culture conditions, and (iii) the 
fact that they are cells of human origin, makes them very useful in regenerative medicine and 
drug safety assessments. More than 400 hESC lines are available, and some of them are well 
characterized and eligible for commercial use. These are organized in international stem cell 
banks, such as the National stem cell bank (www.nationalstemcellbank.org), the UK stem cell 
bank (www.ukstemcellbank.org.uk), the hESCreg (www.hescreg.eu) (Jensen et al., 2009). 
The need to provide cell-based assays that are physiologically relevant to human, without 
these cells losing their functional properties after some time, and that are relatively easy to 
access, is really important for drug discovery and risk assessment. These properties are all 
gathered in hESCs. They provide a source of virtually unlimited cells that are physiologically 
relevant to human cells, which could lower the cost-effective assays leading to lower attrition 
rates and safer drugs by increasing the predictability of the assays (Sartipy et al., 2007). These 
hESCs should be considered to develop into models that facilitate studies on novel targets for 
T2DM therapy, including for example pancreatic lineage and insulin producing β-cells 
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There is a number of methods that have been developed for the differentiation of hESC to 
pancreatic lineage (Kroon et al., 2007; Jiang et al., 2007; D’Amour et al., 2006; Chen et al., 
2009). Due to the difficulties in differentiation, most of the methods are practically 
insufficient, since the final population of β-cells is really low comparison with the total cell 
population  cultured in the beginning. A highly relevant protocol was described by D’Amour 
et al. (2006), taking into consideration the pathway of the pancreas organogenesis. It is a five 
stage process from hESC to β-cell aggregates. The final result is insulin producing cells. 
The five different stages of the differentiation process of the hESC to β-cell, aggregates can 
be described as follows (D’Amour et al., 2006): 
Stage 1: Definitive endoderm (DE): Critical for the direction to pancreatic lineage is the 
differentiation of the human embryonic stem cells into definitive endoderm. This is because 
the differentiation of stem cells is nonreversible under normal cultures conditions (Guo et al., 
2009). Thus the differentiation must be efficient in the sense of the percentage of cells 
differentiated compared with the cells differentiated in a developing embryo. The 
differentiation in this first stage is achieved by exposing the undifferentiated hESCs to activin 
A (100 ng/ml) for 3 days. Wnt3a (25 ng/ml) is added during the first day of activin A 
exposure. The differentiation should approximately reach 80% of the initial cell population. 
The cells at this point should express definitive endoderm’s markers SOX17 and CXCR4 
(D’Amour et al., 2005).  
Stage 2: Primitive gut (PG): To reach stage 2, activin A is removed from the cells. This 
allows the cells to differentiate to primitive gut tube. By adding at this point also FGF10 
(fibroblast growth factor 10) and a Hedgehog inhibitor, KAAD-cyclopamine, for 2-4 days,   
INS mRNA will increase at a later stage (stage 5). At this point gut tube markers HNF1B and 
HNF4A should be expressed along with SOX17. On the other hand definitive endoderm 
markers CER and CXCR4 should be reduced. 
Stage 3: Posterior foregut (PF): After 4 days the cells proceed to stage 3. Along with FGF10 
and KAAD-cyclopamine cells are exposed to retinoic acid (RA) for 2-4 days. By this time 
cells are directed to posterior foregut. RA has been proven to be crucial for the direction to 
pancreatic lineage (Chen et al., 2004). High levels of PDX1 and HNF6 markers should be 
expressed at this point. Parallel an increase of HNF1B and HNF4A should also be observed. 
The differentiation at this point reaches 50% of the initially present hESCs. 
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Stage 4: Pancreatic endoderm (PE): The next stage of the differentiation, stage 4, is achieved 
by the removal of RA. With the removal of RA, after 3 days, the cells differentiate from 
posterior foregut to pancreatic endoderm and endocrine precursor. Co-expression of PDX1 
and NKX1 should be observed, at this point, which represents pancreatic epithelium. In 
addition, many NKZ2-2 expressing cells should co-express NGN3, reflecting initial 
commitment to the endocrine lineage.  At this point of differentiation the differentiated cells 
amount to 35% of the original population. 
Stage 5:  Langerhans islets, that contain β-cells: The last and final stage according to 
D’Amour et al. (2006) is achieved by adding growth factors, such as Ex4, IGF1 and HGH. By 
leaving the cells for at least 3 days to mature, expression of PDX1 and NKX61 should be 
observed. The final differentiated cells (representing β-cells in islets-like aggregates) amount 
to only a relatively low percentage (7%) of the total cell population. These cells respond to 
multiple secretory stimuli but not to glucose, which is also a characteristic of the fetal 
pancreas, indicating that they are immature (D’Amour et al., 2006). 
An additional study from Kroon et al. (2007) described a procedure in which the final 
differentiation step in this process was carried out in vivo and resulted in the formation of 
glucose responsive cells with insulin secretory properties similar in kinetics and magnitude to 
similarly engrafted adult human islets. This was achieved by a direct engraftment of cell 
aggregates of the pancreatic endoderm (stage 4) into immunosufficient mice and generated 
glucose-responsive, insulin-secreting cells providing a very promising cell-replacement 
therapy. 
An alternative option at stage 4 is to maintain RA and transfer cells to modified islet 
maturation medium as described by Jiang et al. 2007. In this modified protocol, bFGF (10 
ng/ml) was added the first 3 days and nicotinamide (10 nM) for the next 5 (Jiang et al., 2007). 
By this, maturation of the cells that are already committed (stage 4) to pancreatic lineage is 
achieved. Using this modified protocol the percentage of hESC differentiated to the final 
stage of differentiation might reach 15% and these cells might even respond to variations in 
glucose levels. 
It is also worth noting that in the method of Chen et al. (2009) they have identified a small 
molecule, (-)-indolactam V (ILV), that induces differentiation of hESCs to a substantial 
number of Pdx-1 expressing cells. This population could release c-peptide following glucose 
stimulation. The ILV has been proven to work specifically at one stage of pancreatic 
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development. It directs the pancreatic specification of hESCs that have already committed to 
the endoderm lineage; that is the gut tube endoderm (stage 3 of the method of D’ Amour et 
al., 2006). According to Chen et al. (2009) one of the remaining challenges is to find 
molecules inducing differentiation to pancreatic lineage when added at each stage and also to 
determine which stage is optimal for transplantation. A suggestion is to aim at identification 
of new chemical compounds to optimize the differentiation process. 
More recent studies pointed in this direction. Several groups studied and/or used insulin 
producing -cells differentiated from hESC to find new genes involved, characterize novel 
compounds that can assist the differentiation or optimizing the existing methods. Schaffer et 
al. (2013) found a gene NKx6.1 (NK6 homeobox 1) that regulates a network responsible for 
pancreatic -cell identity. Likewise Cai et al. (2013) showed that NGN-3 expressing 
progenitors assist in the generation of pancreatic endocrine cells, and Cage et al. (2015) 
showed that ARX (Aristaless Related Homeobox) is a major factor in the specification of 
somatostatin, glucagon and insulin in cells derived from hESCs. Resveratrol is one of the 
compounds that it was shown to improve the maturation of -cells derived from hESCs 
(Pezolla et al., 2015). Also several studies have demonstrated optimization and improvement 
in the steps needed in achieving insulin producing -cells (Wang et al., 2015; Bose et al., 
2012; Richardson et al., 2015), 
Another advantage of stem cell technology is that by understanding the function of stem cells, 
we understand how organisms develop and grow and how tissues are maintained through life. 
A significant knowledge to understand diseases and injuries and how to treat them is revealed 
with the understanding of stem cells. Therefore stem cell technology provides a new tool for 
better understanding the mechanisms involved in drug-induced adverse reactions and to 
potentially predict and avoid toxicity in humans (Davila et al., 2004). 
Future perspective: elucidating the role of resistin in insulin sensitivity. 
Another aspect that deserves attention in future developments is the further elucidation of the 
role of resistin in T2DM. Resistin plays an important role in insulin resistance and in 
inflammation (Mojiminiyi et al., 2007; McTernan et al., 2006; Holcomb et al., 2000; Reilly et 
al., 2005; Fasshauer and Blüher, 2015). Several mechanisms have been proposed for resistin’s 
activity such as inhibition of cell surface glucose transporters, activation of suppressors of 
cytokine signaling (SOCS-3), blocking of insulin signaling pathways, stimulation of hepatic 
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glucose production and activation of free fatty acids release from adipose tissue (Moon et al., 
2003; Steppan et al., 2005; Brown et al., 2007; Sheng et al., 2008; Banerjee et al., 2004; 
Pravenec et al., 2006; Stofkova, 2010; Fasshauer and Blüher, 2015; Al Hannan and Culligan, 
2015). Additionally resistin promotes overall inflammation through TLR-4 (Benomar et al., 
2012). It is obvious that prevention of resistin activity would improve insulin sensitivity 
(Lazar, 2007; Blüher, 2014). Reduction of resistin’s expression may possibly contribute to 
T2DM treatment, and may even not be restricted to treatment of the adverse health effects of 
T2DM. Testing and finding inhibitors or antagonists of resistin from known chemical data 
bases using the methods described in this thesis may prove to be a way forward. Additionally 
blockage of resistin function might be possible with the use of anti-resistin antibodies from 
immunized animals as Steppan and his colleagues showed before (2001) that administration 
of anti-resistin antibodies improved blood sugar and insulin action in mice with diet-induced 
obesity. To further elucidate the role of resistin in T2DM the actual nature and role of the 
receptor of resistin must be further elucidated (Daquinag et al., 2011; Al Hannan and 
Culligan, 2015) since only putative receptors have been reported such as CAP-1 (Lee et al., 
2014), an isoform of decorin (Daquinag et al., 2011), mouse receptor tyrosine kinase-like 
orphan receptor 1 (ROR1) (Sanchez-Solana et al., 2012) and Toll-like receptor 4 (Tarkowski 
et al., 2010). The identification of the actual receptor will reveal the pathophysiological role 
of resistin which in turn will contribute to the development of novel diagnostic tools (Park et 
al., 2013). Considering that resistin protein is found to circulate in the blood and can affect 
multiple tissues and organs a possible way forward would be to perform RNA sequencing in 
samples from all the affected organs from diabetic patients and compare the genes that are 
regulated with their expression levels in non-diabetic patients.  This extended comparison 
might shed light on the actual mechanism behind resistin mediated effects in T2DM and 
reveal possible biomarkers that could be resistin’s receptor or could be used as potential novel 
pharmacological targets. All the above possible findings have to be translated into human 
subjects considering the fact that human and mouse resistin are not homologous (Al Hannan 
and Culligan, 2015; Park et al., 2013; Ghosh et al., 2003; Patel et al., 2004). 
Future perspective: Organokines 
It has been mentioned before that adipose tissue acts as an endocrine organ secreting 
cytokines called adipokines that regulate systemic metabolism and energy homeostasis (Galic 
et al., 2009; Molica et al., 2014; Choi, 2015). Similarly, studies have shown that other organs 
secret proteins that affect whole body metabolism through autocrine, paracrine and endocrine 
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activity (Choi, 2015; Jung et al., 2016) and they are termed in line with the organ from which 
they are secreted. Skeletal muscles secrete myokines and liver secretes hepatokines (Febbraio 
and Pedersen, 2005; Stefan and Haring, 2013). 
Skeletal muscle is considered to be the largest organ, composing 40% of body weight and not 
only contributing to energy storage but also to the depletion of energy (Eckardt et al., 2014; 
Roden, 2015; Samuel and Shulman, 2012). Skeletal muscle is now characterized as an 
endocrine organ (Febbraio et al., 2005; Pratesi et al., 2013). Hundreds of proteins have been 
identified to be secreted by skeletal muscle but more recently 50 novel myokines have been 
identified that cross-talk with other tissues such as adipose tissue, liver and pancreas and their 
regulation may improve insulin resistance (Eckardt et al., 2014; Raschke et al., 2013; Hartwig 
et al., 2013; Norheim et al., 2011; Gamas et al., 2015). Skeletal muscle’s secretion of 
myokines depends on their contractile activity and this may be proved to be the link of 
physical exercise and health promoting effects of exercise (Eckardt et al., 2014). Also 
physical inactivity is shown that is a risk factor for a number of diseases including T2DM and 
cardiovascular disease (Tuomilehto et al., 2001; Nocon et al., 2008; Pedersen, 2010; Ertek 
and Cicero, 2012). Here it is mentioned one example of these myokines which is interleukin-6 
(IL-6) (Ahima and Park, 2015; Eckardt et al., 2014). IL-6 was the myokine that was found to 
be secreted first in the blood upon muscle contraction and is also known as proinflammatory 
cytokine (Choi, 2015). IL-6 is secreted mainly by macrophages but during exercise, is also 
secreted by myofibres (Hiscock et al., 2004). IL-6 improves insulin sensitivity during acute 
exercise but induces insulin resistance in adipose tissue and in liver when its levels are 
chronically elevated (Catoire and Kersten, 2015). When secreted by macrophages then its 
signaling is regulated by the NF-kB pathway but when it is secreted by the myofibres then it 
is regulated mainly by Ca2+/nuclear factor of activated T-cells (NFAT) and glycogen/p38 
mitogen-activated protein kinase (MAPK) pathways (Brandt and Pedersen, 2010, Pedersen, 
2010). The ratio of muscle to immune cell is considered to be responsible for the anti-
inflammatory or proinflammatory properties of IL-6 (Pedersen and Fabbraio, 2008, Pedersen, 
2010). When the balance is on the antiflammatory side then IL-6 has a beneficial role in 
insulin sensitivity and glucose homeostasis (Pedersen and Fabbraio, 2007).  
Comparable to proteins secreted form skeletal muscles, liver also secretes proteins, 
hepatokines, that regulate whole body homeostasis through the regulation of glucose and lipid 
metabolism and cross-talking with other tissues (Stefan and Haring, 2013; Iroz et al., 2015). 
Yoo et al. have shown that hepatokines are a link between obesity and cardiovascular 
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diseases. Two examples of such hepatokines are Fetuin-A and Fibroblast growth factor 21 
(FGF21). Fetuin-A proved to play an important role in metabolic disease (Iroz et al., 2015). 
Elevated levels of Fetuin-A were observed in obese subjects and are correlated with insulin 
resistance and glucose intolerance through the inhibition of tyrosine kinase activity of the 
insulin receptor and the inhibition of GLUT4 (Iroz et al., 2015; Stefan and Haring, 2013; 
Takata et al., 2009). Additionally Fetuin-A may induce inflammation and insulin resistance as 
it is characterized as an adaptor protein for saturated fatty acid mediated TLR-4 activity (Pal 
et al., 2013; Mukhopadhyay and Bhattacharya, 2016). Consequently, Fetuin-A is contributing 
to the development of T2DM (Heinrichsdorff et al., 2012; Andersen et al., 2008; Mathews et 
al., 2002). On the other hand FGF21 proved to be beneficial to glucose metabolism and lipid 
homeostasis (Iroz et al., 2015). FGF21 has the ability to induce rapid loss of weight in rodents 
and to reduce blood glucose levels by stimulating glucose uptake in human primary 
adipocytes without the help of insulin (Kharitonenkov and Adams 2014). The beneficial 
effects of FGF21 have been translated to non-human primates and obese patients with T2DM 
which makes it a promising pharmacological target (Iroz et al., 2015; Gimeno et al., 2014). 
These recent discoveries, recognitions and characterizations of novel organokines seem to 
provide a proof and a motive to continue unravelling the secretome of such complex diseases. 
And in order to decipher the secretome and identify novel biomarkers that can be used as 
pharmacological targets new robust and unequivocal methods have to be developed (Park et 
al., 2015, Bajaj and DeFrozo, 2003). 
Future perspective: Incretin effect 
The incretin effect is defined as the increase in glucose-dependent insulin secretion in 
response to nutrients, in comparison to glucose infused intravenously (Holst and Orskov 
2004; Nauck 2016; Lutz and Osto 2016). In T2DM the incretin effect is decreased (Nauck 
2016). Incretin hormones such as the gastrointestinal peptide hormone glucagon-like peptide 
1 (GLP-1) bind to GLP-1 receptor and promote the release of insulin secretion from 
pancreatic β-cells (de Graaf et al. 2016). Additionally GLP-1 has been shown to play a role in 
different models that promote β-cell proliferation, neogenesis and inhibit apoptosis (Buteau 
2011; Perfetti et al. 2011; de Graaf et al. 2016). Therefore finding agonists for the GLP-1 
receptor can be a promising tool to define novel drug targets for T2DM. However the half life 
of GLP-1 is very low (2 min) because of degradation by dipeptidyl  peptidase-4 (DPP-4) 
(Drucker and Nauck 2006; Nauck 2016). Thus the therapeutic strategies so far focus on either 
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extending the half life of GLP-1 by reducing its degradation via inhibitors of DPP-4 or 
defining GLP-1 agonists with longer half lives. Progress has been made in this field and the 
first GLP-1 agonist discovered, exenatide, has a half life of 2.4 h while the latest agonist 
which is albiglutide has a half life of 5 days. Furthermore DPP-4 inhibitors have been 
demonstrated to reduce DPP-4 activity maintaining elevated levels of GLP-1 concentrations 
(Ahren et al. 2004, Nauck 2016). Several selective inhibitors have been reported until now 
such as sitagliptin, saxagliptin, linagliptin and alogliptin (Nauck 2016).  
Future perspective: SGLT-2 inhibitors 
Another strategy that is recently used for the treatment of T2DM is the inhibition of sodium-
glucose transporter-2 (SGLT-2). SGLT-2 is responsible for almost 90% of the reabsorption of 
glucose in the blood after it is filtered into the pro-urine in the kidney (Schwartz and Ahmed 
2016; DeFrozo et al. 2012). Increased expression and activity of SGLT-2 is observed in 
T2DM patients (Schwartz et al. 2016). Increased expression of SGLT-2 results in increased 
reabsorption of glucose and makes that glucose excretion in the urine occurs only when 
plasma glucose levels are high, sustaining in this way hyperglycemia (DeFrozo et al. 2013; 
Schwartz et al. 2016). The role of SGLT-2 inhibitors is to decrease glucose reabsorption 
leading to excretion of glucose in the urine, thus facilitating lowering glucose plasma levels 
(Reed 2016; Scheen 2016; Jabbour et al. 2012; DeFrozo et al. 2012; Schwartz et al. 2016). 
Examples of SGLT-2 inhibitors are canagliflozin, dapaglifloxin and empagliflozin. 
Future perspective: Cholesterol arachidonate ester 
According to our findings from RNA sequencing of human adipocytes exposed to resistin 
(chapter 4), c11orf10 gene is up regulated. This gene, according to Tanaka et al. (2008) is 
associated with the FADS (fatty acid desaturate) genes, which in turn are associated with 
elevated levels of polyunsaturated fatty acids (PUFAs) and arachidonic acid (Guan et al., 
2015). The increase of cholesteryl esters is correlated with insulin resistance (Melone et al., 
2012). Based on the results of our pilot experiments it can be speculated that this cholesterol 
ester is cholesterol arachidonate ester. Therefore a suggestion is that regulation of cholesterol 
arachidonate ester by resistin is another mechanism of resistin towards insulin resistance and 
T2DM. Also from pilot experiments reported in the present thesis, in which gene expression 
was analysed in adipocytes exposed to resistin in combination with cholesterol ester 
arachidonate possible target genes that showed up or down regulation were identified such as 
Ribosomal Protein L11 (RPL11), Rho-associated Protein Kinase 2 (ROCK2), Integrinalpha-6 
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(ITGA6), Acidic Ribosomal Phosphoprotein P0 (RPLP0) and Basic Transcription Factor 3 
(BTF-3). These genes were regulated to a high extent but not significantly, thus giving us 
only indications and not solid proof for their resistin mediated regulation. Further 
investigation is needed about these new possible targets to verify their role in insulin 
sensitivity. 
Conclusions 
In this thesis new therapeutic targets for treatment and prevention of T2DM were investigated 
and identified. The fact that T2DM is a systemic disease makes it hard to identify specific 
targets and makes identification of novel drug targets a complex problem. Nevertheless the 
approaches described and results obtained pointed at some new targets that can be used in the 
future to identify new drug development strategies. There is sincere hope that the models 
developed in the present thesis will contribute to the definition of novel therapeutic strategies 
and enable answering some questions about a disease that has been studied for a very long 
period, although at the same time it is acknowledged that there are a lot of remaining 
questions for a complex endpoint.   
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Summary  
Type 2 Diabetes Mellitus (T2DM) is a modern metabolic disorder. T2DM is related with 
modern lifestyle and results when the body is unable to produce sufficient insulin or respond 
properly to insulin, which is the hormone that regulates the levels of glucose in blood. The 
aim of this project was to define novel targets for the possible development of drugs for 
T2DM. 
Chapter 1 introduces the topic and offers an overview of T2DM and the mechanisms behind 
it. T2DM results when there is impaired insulin production by beta-cells of the pancreas and 
from the inability of the peripheral organs to respond properly to insulin by adequate glucose 
uptake from the blood, reflecting insulin resistance. Insulin sensitizing drugs such as 
thiazolidinediones (TZDs) and their analogues are currently used for the treatment of T2DM. 
New directions though are shown since insulin resistance started to be correlated with obesity 
and inflammation and new targets, like adipokines, might proof to be of value as potential 
targets for the development of drugs that counteract the effects of T2DM. 
In chapter 2 we focused on a possible novel target for insulin therapy which is the adipokine, 
resistin. It is shown that resistin downregulation in mouse adipocytes would provide an 
alternative for PPARγ agonist activity, the mode of action of TZDs. To this purpose a reporter 
gene cell line for PPARγ activation was used and a series of TZDs were tested, obtaining 
EC50 values for PPARγ activation for each one. The same TZDs were also tested for effects 
on resistin mRNA expression in adipocytes. The results showed that TZDs with the lowest 
EC50 for PPARγ activation had also the lowest IC50 for resistin mRNA downregulation. More 
specifically the results revealed a significant correlation between the EC50 for PPARγ 
activation in a reporter gene cell line and the IC50 for resistin downregulation in adipocytes. 
The outcomes indicate that PPARγ mediated downregulation of resistin might promote 
insulin sensitivity and that resistin can be used as a target for searching insulin sensitizing 
compounds.  
In chapter 3 we used a commercially available reporter gene cell line (HEK-Blue-TLR-4) to 
investigate whether detection of TLR-4 mediated gene expression could be a possible 
bioassay to detect candidate antidiabetic drugs able to inhibit resistin mediated TLR-4 
activation and subsequent effects. Firstly it was shown that resistin can activate TLR-4 
signaling in the TLR-4 reporter gene assay similar to the natural ligand of TLR-4 which is 
lipopolysaccharide (LPS). Inhibition of LPS mediated TLR-4 signaling by two known TLR-4 
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inhibitors could be demonstrated as well as inhibition of resistin mediated TLR-4 signaling by 
these two known TRL-4 inhibitors. It was concluded that the TLR-4 reporter gene cell line 
provides a novel tool for detection of resistin antagonists and might be of use as a new target 
to screen for a possible new type of antidiabetic drugs. 
To further increase the possibility for identification of novel targets for antidiabetic drugs via 
the possible role of resistin, in chapter 4 the mechanism behind resistin mediated effects was 
investigated. More specifically adipocytes were exposed to resistin and the effects on gene 
expression were analysed by RNA sequencing. Large sets of genes were upregulated or 
downregulated. It was observed that resistin dependent differentially expressed genes were 
involved in downscaling cellular maintenance and cellular processes and in lipid storage. 
Based on these observations it was proposed that resistin dependent gene expression is related 
to modifications in cellular maintenance processes, slowing down metabolic changes resulting 
in energy conservation. Under these circumstances of metabolic adaptation in the presence of 
resistin, excess food consumption as in modern societies can result in obesity, inflammation 
and insulin resistance. 
In chapter 5 an in vitro model was introduced for the search on novel targets for T2DM that 
mimics inflamed adipocytes. Adipocytes (3T3-L1) were co-cultured directly with activated 
macrophages (RAW264.7) producing an environment for testing compounds under conditions 
more similar to the in vivo situation in T2DM patients.  Quantitative mass spectrometry 
analysis on the co-cultured cells identified clinically known biomarkers, thus confirming the 
assay. At the same time 54 new proteins that have the potency to be used for research into the 
mechanism of T2DM were found. Additionally comparison of our results to a study on human 
visceral fat of obese non-diabetic and obese diabetic patients, indicated that AUH, NAGK, 
pCYT2, NNMT, STK39 and CSNK2A2 have the potential of being prognostic biomarkers. 
Chapter 6 discusses the strategies described in the thesis and gives future perspectives for the 
detection of novel targets to screen for new drug candidates for the treatment of T2DM.  
Although T2DM has been studied for a very long period its complexity and systemic nature 
raises more questions. Altogether it is believed that the strategies presented in this thesis will 
contribute in answering some of the questions, defining possible novel targets for the 
development of new drugs candidates for T2DM.  
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